Ryman Healthcare Limited logo

Ryman Healthcare reports 1H26 results

Half Year Results26 November 2025RYMHealthcare

RYMAN HEALTHCARE LIMITED 1
NZX, ASX & MEDIA RELEASE

Ryman Healthcare reports 1H26 results

27 November 2025

Ryman Healthcare Limited (Ryman) today announced its results for the six months ended 30

September 2025, delivering its first positive free cash flow

1

result in a decade.

Chief Executive Officer Naomi James said the result represents a major milestone in Ryman’s

transformation.


“We’ve turned an important corner in our transformation, with the balance sheet reset providing a

robust foundation for sustainable performance. The business has stabilised, momentum is returning,

and we are delivering results with meaningful progress achieved against FY26 priorities. Our focus is

now moving to accelerating performance across our portfolio of high quality retirement villages.”


Cost-out initiatives are tracking ahead of expectations, while a refreshed sales strategy is rebuilding

momentum and demonstrating confidence in Ryman’s new standard 30% deferred management

fee (DMF) offering.


Following its $1.0 billion equity raise in February 2025 and the full refinancing of its $2.0 billion bank

facilities in November, Ryman’s balance sheet reset is now complete with its new funding structure

aligned with its operating model.


Operational highlights

• Pricing model changes fully embedded with significant uplift in average DMF on ORA sales

from 20.7% in 1H25 to 28.8% in 1H26

• Sales volumes rebuilding with two quarters of sequential growth; 704 sales in 1H26 (Q1: 337 /

Q2: 367)

• Increasing utilisation of recently delivered care capacity and strong growth in room pricing

• Kevin Hickman main building and final stage at Nellie Melba both completed in July 2025

Financial highlights

• First positive free cash flow

1

result in over a decade of $56 .2 million

• Total revenue up 13%, with growth in both pricing and utilisation, while total costs fell 2%

• Net loss after tax of -$45.2 million (-4.4cps) with reduced fair value movement from the prior

year but with property valuations stable in 1H26

• Full bank refinancing achieved of $2.0 billion with an average facility tenor of five years and

improved pricing and covenants

Strategic highlights

• Annualised cost-out

1

achieved to date of $40 million; FY26 target now lifted to $50–60 million

(from $46 million) as turnaround advances

RYMAN HEALTHCARE LIMITED 2
• Strategy and capital management review progressing with update to be provided at an

investor day on 3 February 2026

• The New Zealand Government’s formation of a Ministerial Advisory Group to recommend

changes to the aged care funding model marks an important step toward sector reform

and long-term sustainability.

Financial results

Ryman’s financial performance has strengthened significantly with total revenue growth of 13%

underpinned by its increasing resident base and strong fee growth. Total costs fell 2%, driven by

cost-out initiatives gaining traction, stronger performance across both mature and developing

villages and lower interest costs. This led to a $57.6 million reduction in losses before tax and fair

value movements

1

.

Free cash flow lifted to $56.2 million, up $108.7 million, driven primarily by strong development cash

flows, reflecting new units being sold down and the scaling back of development investment. Cash

flow from existing operations was broadly flat, with improving cash from village operations offset by

increased bought back stock on hand.

Net profit declined from $82.0 million in 1H25 to a loss of -$45.2 million, with the improvement in

operating earnings being offset by lower fair value movements. Earnings per share declined from

11.9cps to -4.4cps, reflecting lower profit and higher shares on issue.

First time segmentation of retirement village and aged care financials has provided greater insight

to business performance, aligned with FY26 strategic priorities.

Sales and operational performance

Improved sales performance and disciplined execution drove a clear rebuild in sales momentum in

the first half. Higher contract conversions were supported by quality leads from well-attended

village open days and targeted pricing and incentives. As a result, Ryman has lifted FY26 sales

guidance to 1,300–1,400 ORA sales, up from the previous range of 1,100–1,300.

Total vacant RV stock increased from 1,239 at March 2025 to 1,335 at September 2025, partly due

to the delivery of 179 new units, including major apartment stages at Kevin Hickman and Nellie

Melba. Vacant RV stock under contract increased slightly from 367 to 380, supported by a stronger

focus on lead quality reflected in improved conversion rates and settlement times.

James said: “We remain focused on selling down stock as a significant opportunity to drive cash

flow. We are confident our sales effectiveness will support continued progress over FY26.

Importantly, our significantly higher DMF value on new contracts will underpin revenue growth and

improved business performance in the years ahead.”

Resident sentiment remains positive with net promoter scores (NPS) improving across all

accommodation types in 2025 and recognised externally through awards voted on by residents

and their families.

Aged care occupancy is high across Ryman’s mature villages, with capacity in five recently

opened care centres filling ahead of expectations, demonstrating strong demand for Ryman’s high

quality aged care offering. Care pricing has seen robust growth year on year, with average daily

room premiums up 10% in New Zealand and average refundable accommodation deposit (RAD)

balances up 5% in Australia.

Development update

Following a comprehensive Trans-Tasman recruitment process, Ryman Healthcare is pleased to

share the appointment of Richard Stephenson as Chief Development and Property Officer. Richard

brings deep sector experience, with more than 20 years working across the retirement living and

RYMAN HEALTHCARE LIMITED 3
aged care sectors in New Zealand and Australia. The addition of Richard to the Senior Executive

Team positions Ryman for a return to disciplined growth and supports the continued delivery of

high-quality communities for residents.

Richard will join Ryman in early 2026 and will lead development and property functions across New

Zealand and Australia.

Delivery of remaining in-flight projects is progressing to plan, with sites under active development

down from seven to four.

The opening of the Kevin Hickman main building in July marked the fifth main building opened in

the past 18 months. The final stage of Nellie Melba opened in July, completing the village. The main

buildings at Northwood and Patrick Hogan are under construction and expected to open in mid-

2026 and the first half of 2027 respectively. Remaining stages at Hubert Opperman have

undergone a comprehensive redesign, reducing capital intensity and optimising unit mix to better

meet market demand. Updated plans are expected to be finalised and approved next calendar

year, allowing for the commencement of construction, which will be delivered under the

outsourced model.

The timing of future stages at developing villages will be aligned with market demand, reflecting

Ryman’s commitment to a disciplined approach to growth.

“At our investor day in February, we’ll share more on the land bank review, including sites which

have been earmarked for future development and additional sites selected for divestment. We’re

pleased to have already secured two sales from the review, with Park Terrace contracted for $42

million and Mount Eliza for $35 million in recent weeks.” said James.

Aged care reforms progressing

Ryman welcomes the New Zealand Government’s announcement of a Ministerial Advisory Group

to ensure the aged care sector can sustainably meet future demand.

“This is a critical step toward addressing the funding gap in aged care. Sustainable funding is

essential to both maintaining existing capacity and growing the additional capacity needed for

future growth in demand, and we are ready to play our part in the solution.” said James.

The Ministerial Advisory Group will provide direct advice to the Ministers of Health and Seniors on

reforms to New Zealand’s aged care funding model. The group will deliver its recommendations

ahead of the 2026 General Election, with the Government signalling its intention to implement

changes from 2027.

Earlier this year, Ryman confirmed it was reviewing its aged care bed capacity in New Zealand due

to sector-wide underfunding, and two care centres have since been closed.

Recent reforms to the Australian Aged Care Act are enhancing the Government’s co-contribution

funding model, with clinical costs fully government-funded and accommodation and other living

costs means-tested. Changes to refundable accommodation deposits (RADs) - including a 2%

annual retention capped at 10% over five years - are expected to generate a meaningful revenue

uplift.

Balance sheet reset complete

In November 2025 Ryman successfully completed a full refinancing of its $2.0 billion syndicated loan

facilities, extending the average tenor to five years and introducing a new structure that enhances

flexibility and better aligns with Ryman’s operating model.

In addition, Ryman listed on the ASX on 1 October 2025, broadening access for Australian and

international investors to a proven operator with the largest retirement living and aged care

business in New Zealand and a growing footprint in Australia.

RYMAN HEALTHCARE LIMITED 4
Ryman is undertaking a review of its capital management framework in FY26, including its dividend

policy, with an update to be provided at the February 2026 investor day.

Net tangible assets (NTA) per share is down slightly to $4.06 at 30 September, reflecting steady

investment, property valuations and previously announced restatements to the March 2025

balance sheet relating to suspended contributions.

Industry recognition

In October, Ryman won several resident and family-voted awards, including National Best Group

Provider, the Aged Care Large Facility South Island Award for Ernest Rutherford Village, and an

Enduring Excellence Award for Diana Isaac Village at the Seniors New Zealand ‘NZ’s Best Awards’

for retirement villages and aged care facilities.

“Our team feels privileged to serve more than 15,000 residents who call Ryman villages home and

make our communities such special places to live.” said James.

Outlook

Sales in the second half of FY26 are expected to remain broadly in line with the first half, reflecting

mixed market conditions and the timing of unit delivery, which was weighted toward the first half.

We anticipate ongoing variability as the property markets recover at differing speeds - Victoria is

showing positive momentum while Auckland is yet to show meaningful improvement.

Cost-out initiatives are ahead of plan, with annualised costs savings achieved up from $23 million at

March 2025 to $40 million at September 2025. Ryman now expects to achieve annualised savings of

$50 –60 million by the end of FY26, up on prior guidance.

Updated FY26 guidance:

• Sales of ORAs

2

(occupation basis) of 1,300 to 1,400 at higher DMF (FY25: 1,523, previous

guidance: 1,100–1,300)

• Annualised cost saving target

1

of $50–60 million (FY25: $23 million, previous guidance: $46

million)

• Build rate of 330 including 80 aged care beds and 250 RV units (FY25: 950, previous

guidance: 266–330)

• Capex

1

of $235 –265 million (FY25: $535.3 million, previous guidance: $260–320 million)

including $170 –190 million on development activity (FY25: $458.2 million, previous guidance:

$180-230 million) and $65 –75 million on existing operations (FY25: $77.1 million, previous

guidance: $80–90 million)

• Ryman's guidance for FY26 reflects the current environment and its assessment of future

trends.


“Our near-term focus remains on continuing to build sales momentum, releasing cash from the

business and driving operational efficiencies. Ryman is well positioned for cash flow growth with

significant leverage to a housing cycle rebound, New Zealand aged care funding reforms, the

strengthening demographic tailwinds from an ageing population and growing scarcity of quality

care.” said James.


Footnote 1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted

Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be

comparable to similar financial information presented by other entities.

Footnote 2: Reported sales figures reflect retirement village units only and exclude refundable accommodation deposits (RADs) and ORAs on

aged care accommodation.

RYMAN HEALTHCARE LIMITED 5
ENDS

Authorised by

Morgan Powell

General Counsel


About Ryman

Ryman Healthcare was founded in Christchurch in 1984 and owns and operates 49 retirement

villages in New Zealand and Australia. Ryman villages are home to 15,300 residents, and the

company employs 7,800 staff.



Contacts

For investor relations information

Hayden Strickett, Head of Investor Relations

hayden.strickett@rymanhealthcare.com



For media information

Sarah Greig, GM Corporate Affairs &

Communication

sarah.greig@rymanhealthcare.com

---

RYMAN HEALTHCARE | 1H26 Results Presentation1
RYMAN HEALTHCARE

Half year results

For the six months ended 30 September 2025

Presented 27 November 2025

RYMAN HEALTHCARE | 1H26 Results Presentation
Highlights 3

Sales and stock 7

Operations 13

Development 17

Financials 21

Capital management 33

Outlook and strategic priorities 36

Q&A 40

Development updates 41

Appendices 47

All figures in this presentation are in New Zealand dollars (NZD) and are at 30 September 2025 or for the

six months ended 30 September 2025, unless otherwise stated. AUD balances at 30 September 2025 are

converted at an NZD/AUD rate of 0.8771.

AgendaPresenters

Matt Prior

CHIEF FINANCIAL OFFICER

Naomi James

CHIEF EXECUTIVE OFFICER

2

RYMAN HEALTHCARE | 1H26 Results Presentation3
Highlights

Keith Park Village residents Jill and Paddy

3

RYMAN HEALTHCARE | 1H26 Results Presentation4
Opening remarks

1

First positive free cash flow

1

result in a decade

of $56.2 million

2

Annualised cost-out

1

achieved to date of

$40 million; FY26 target lifted to $50–60 million

(previous guidance of $46 million)

3

Sales effectiveness delivered rebuild in first half

volumes with two quarters of sequential growth

4

Full bank refinance complete with enhanced

structure and lifting average tenor to five years

5

Investor day planned for 3 February 2026 covering

strategy refresh and new capital management

framework

Highlights

William Sanders Village resident Madeline

4

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under

GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in

understanding Ryman's performance. It may not be comparable to similar financial information presented by

other entities.

RYMAN HEALTHCARE | 1H26 Results Presentation5
Sales

performance

•Rebuild in sales volumes throughout first half with total sales of 704 ORAs (Q1: 337 / Q2: 367)

•Pricing model changes fully embedded with average DMF of 28.8% achieved on 1H26 sales

Operating

reset

•Annualised cost-out

1,2

increased to $40 million in 1H26; FY26 target lifted to $50–60 million

•Operating EBITDAF

1

up $26.4 million (+193%) driven by performance improvement across mature

and developing villages and reduction in non-village costs

Financial

performance

•First positive free cash flow

1

result in a decade of $56.2 million

•Total revenue up 13%, with growth in both pricing and utilisation, while total costs fell 2%

•Earnings per share of -4.4cps down from 11.9cps, with improvement in operating earnings offset by

lower fair value movements and higher shares on issue

Capital

management

•Full bank refinancing achieved of $2 billion with an average facility tenor of five years and

improved pricing and covenants

•ASX foreign exempt listing completed, broadening access for investors

Portfolio

review

•Strategy and capital management review progressing with update to be provided at an investor

day on 3 February 2026

•Two additional land bank sites sold, bringing total contracted sales to $110 million

3

First half highlights

Ryman has driven accelerated cost-out, made significant progress in rebuilding sales momentum, restored positive

cash flow,and completed a comprehensive debt refinancing

Highlights

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in

understanding Ryman's performance. It may not be comparable to similar financial information presented by other entities. 2: Cash improvement. 3: Park Terrace and Mt Eliza land sales were contracted subsequent to 30

September 2025 (refer to Note 16 in Ryman’s Interim Consolidated Financial Statements for further detail). $110 million includes Nellie Melba excess land, Park Terrace and Mt Eliza (which remain unsettled), along with Karori, which

was settled subsequent to the reporting date.

RYMAN HEALTHCARE | 1H26 Results Presentation6
1H26 performance

Build rate

259

-61% | 1H25: 667

Aged care occupancy

(mature villages)

96.1%

1H25: 96.4%

Unoccupied RV unit stock

1,335

+96 | March 2025: 1,239

Total: 91.1%

Developing: 66.5%

Contracted: 380

Uncontracted: 955

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's

performance. It may not be comparable to similar financial information presented by other entities. 2: 1H25 restated due to new accounting policies applied in FY25.

RV units: 179

Care beds: 80

RV unit occupancy

(mature villages)

91.8%

March 2025: 92.8%

Capex

1,2

$122.1m

-$201.1m | 1H25: $323.2m

EBITDAF per aged care bed

(annualised)

1

$15.3k

Total: 86.6%

Developing: 78.0%

Average ORA sales price

$789k

+0% | 1H25: $788k

Sales of RV unit ORAs

(occupation basis)

704

-15% | 1H25: 827 | 2H25: 696

New sales: 166

Resales: 538

6

RYMAN HEALTHCARE | 1H26 Results Presentation

Highlights

Free cash flow

1

$56.2m

+$108.7m | 1H25: ($52.5m)

RYMAN HEALTHCARE | 1H26 Results Presentation7
Sales and stock

Deborah Cheetham Village

77

RYMAN HEALTHCARE | 1H26 Results Presentation8
279

324

285

219

264

274

101

123

109

83

73

93

380

447

394

302

337

367

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

ResalesNew sales

Turnaround in sales momentum

Sales volumes rebuilding throughout the first half with two quarters of sequential growth

Quarterly sales of ORAs

1

•Continued improvement in sales

effectiveness and contract conversion

following slower 2H25 which was impacted

by concurrent pricing model changes and

organisational restructure

•Quality lead generation from well-attended

village open days and targeted pricing and

incentives at villages with higher stock

•Sales totaled 704 in the first half, down on

827 in 1H25 and broadly in-line with 696 in

2H25

•FY26 guidance lifted to 1,300–1,400 ORA sales

(previously 1,100–1,300)

1: Reported sales figures reflect retirement village units only and exclude refundable accommodation deposits (RADs) and ORAs on aged

care accommodation. Q2 FY26 sales reported in second quarter trading update on 9 October 2025 (link

).

+12%

QoQ

+9%

QoQ

First half performance

Sales and stock

Post pricing model changes

RYMAN HEALTHCARE | 1H26 Results Presentation9
Pricing model changes now fully adopted

First half sales demonstrate confidence in Ryman’s standard 30% DMF offering

•Pricing changes fully embedded across new

contracts centred on a standard 30% DMF

offering

•Delivering significantly higher DMF on sales up

from 20.7% to 28.8% YoY

•Approximately 60% uplift

1

on weekly fees for

rollovers on independent units

•Revenue uplift from contract changes will

build over time, with annual portfolio

turnover currently at 12%

New resident

2

sales by DMF type

1: Difference between average weekly fee on new sales vs average weekly fee for exiting residents. 2: Excludes residents who have transferred

internally from other Ryman units which are included within non-GAAP sales metrics.

1H252H251H26

Average DMF

2

20.7%22.8%28.8%

99%

94%

94%

91%

70%

10%

0%

1%

1%

3%

6%

10%

1%

5%

5%

5%

22%

75%

0%

3%

2H231H242H241H252H251H26

20%25%30%35%40%

Sales and stock

Post pricing model changes

RYMAN HEALTHCARE | 1H26 Results Presentation10
Progressive rebuild in sales contracts

Improvement in sales effectiveness driving stronger contracting activity

663

697

853

827

452

674

2H231H242H241H252H251H26

Net sales contracts

1

1: Net sales contracts reflect signed RV unit applications, including internal transfers from existing residents, less cancelled applications. Net

sales contracts are a lead indicator to booked sales, with the latter being recognised when a resident takes occupation of an RV unit which

typically aligns with settlement.

Sales and stock

Contracted RV unit stock

459

519

513

522

367

380

2H231H242H241H252H251H26

•Solid first half for net sales contracts driven

by growing gross contracts and lower levels

of cancelled contracts

•Expect ongoing variability as local property

markets recover at differing speeds –

Victoria recovering, mixed across regions

throughout New Zealand with Auckland yet

to show meaningful improvement

•Level of contracted stock increased slightly

in the half, with stronger focus on lead

quality reflected in improved conversion

and settlement times

•Contracted stock is lower than 1H25

due to reduced pre-sales as new units are

delivered and development slows

Post pricing model changes

Post pricing model changes

RYMAN HEALTHCARE | 1H26 Results Presentation11
•Resales volumes up 7% on 2H25 and down

11% on a record 1H25

•Turnover rates reflect portfolio maturity,

replenishing resales stock and unlocking

capital gains in the portfolio

•Focus remains on increasing sales volumes to

match turnover

•Payout balance

1

of $277 million at 30

September 2025 provides significant cash

release opportunity with current pricing for

these units approximately $330 million

•Average resales pricing broadly stable YoY,

and down HoH due to regional mix, with

targeted pricing strategies in place for

higher stock villages and stable or increasing

prices in low stock villages

•Gross resales margins continue to moderate

from historical highs, reflecting flat house

price inflation environment

Resales of ORAs

Rebuild in sales volumes with average pricing broadly stable despite challenging market conditions

Resale volumesAverage resales ORA price

Gross resales margin

2

Turnover (units vacated)

272

287

278

237

252

279

289

325

267

286

551

576

603

504

538

1H242H241H252H251H26

IndependentServiced

$884k

$868k

$895k

$922k

$874k

$581k

$578k

$578k

$594k

$586k

1H242H241H252H251H26

IndependentServiced

37.1%

32.7%

33.9%

32.9%

27.3%

19.6%

18.6%

16.8%

14.5%

11.0%

1H242H241H252H251H26

IndependentServiced

Sales and stock

571

592

628

572

619

1H242H241H252H251H26

1: Gross amounts (inclusive of DMF) paid out on existing RV units for vacating residents or internal transfers where the unit has not been settled

under a new ORA. 2: The difference between the previous purchase price of an ORA and its new purchase price divided by the new purchase

price. Excludes resident incentives, selling costs, suspended contributions and unit refurbishment costs.

RYMAN HEALTHCARE | 1H26 Results Presentation12
New sales of ORAs

Disciplined stock delivery and pricing actions taken to unlock new sales cash opportunity

Average new sales priceNew sales stock

New units completedNew sales volumes

•Reduction in new sales reflects progressive

ramp down of development and continued

elevated industry stock in some locations

•Independent stock reduced as sales

outpaced deliveries for three consecutive

half-year periods

•Higher than typical serviced apartment

stock from significant deliveries in committed

developments over past 18 months

•Reviewing options to increase serviced

apartment utilisation

•Targeted pricing and fee initiatives rolled out

across villages with aged stock or

heightened competition

•Strong average new sales pricing reflects

favourable village and country mix, with 45%

of new sales from Australia

•Total new sales stock value of $470 million

provides significant cash release opportunity

165

162

169

164

131

71

49

55

28

35

236

211

224

192

166

1H242H241H252H251H26

IndependentServiced

$1,045k

$1,025k

$1,035k

$1,049k

$1,092k

$654k

$699k

$726k

$655k

$689k

1H242H241H252H251H26

IndependentServiced

288

176

142

159

114

101

245

45

65

389

176

387

204

179

1H242H241H252H251H26

IndependentServiced

Sales and stock

317

331

304

300

284

119

69

260

278

308

1H242H241H252H251H26

IndependentServiced

RYMAN HEALTHCARE | 1H26 Results Presentation13
Operations

Kevin Hickman Village bowling tournament

13

RYMAN HEALTHCARE | 1H26 Results Presentation14
14

RYMAN HEALTHCARE | 1H26 Results Presentation15
$654k

$671k

$681k

$694k

$718k

1H242H241H252H251H26

$50.5

$52.2

$54.1

$57.4

$59.5

1H242H241H252H251H26

Aged care performance

Growing care utilisation in developing villages and robust pricing outcomes

•Strong growth in room premiums in New

Zealand (up 10% YoY) with consistently high

occupancy

•Base care funding uplift of 4.0% in New

Zealand effective from 1 July 2025

•RAD growth in Australia driven by refreshed

pricing framework

•Growing utilisation with average vacant

beds in developing villages reducing by 46

in the half

•Maintained high occupancy in mature care

centres; down slightly YoY impacted by

challenging winter

•Recently opened Kevin Hickman care

centre (80 beds) now over 50% occupied

3

,

following planned closure of two rest-home

only level care centres in Christchurch

(95 beds)

•‘Resident Fund’ product to facilitate capital

transfer into care successfully trialled, now

being rolled out across NZ portfolio

Average daily room premiums

– New Zealand ($ per day)

Average RAD balance

– Australia (AUD)

10%

YoY

Average vacant beds in

developing care centres

1

133

143

234

315

269

1H242H241H252H251H26

1: Includes all care centres which aren’t considered mature. 2: Excludes developing care centres which have not yet reached 90% occupancy for a

full financial year, and an additional three villages from 1H25: Edmund Hillary (hospital care wing recently reopened following relevelling works),

Margaret Stoddart and Woodcote (progressive bed closures in 1H26). 3: At November 2025.

Operations

Mature care centre occupancy

2

96.2%

96.3%96.4%96.3%

96.1%

1H242H241H252H251H26

5%

YoY

RYMAN HEALTHCARE | 1H26 Results Presentation16
Aged care reforms progressing

Major reforms taking effect in Australia; commitment to near-term reforms in New Zealand

•Co-contribution model with clinical costs fully funded by

the Australian Government and accommodation and

other living costs means-tested

•Retention on new RADs introduced at 2% per annum,

capped at 10% over five years, delivering a projected

$6.4 million annualised benefit

2

•Twice yearly indexation of daily accommodation

payments (DAPs) to better reflect cost movements

•New'Support at Home’ program replaces 'Home Care

Packages’

•Impact of funding changes to the hotelling supplement

and AN-ACC pricing, announced on 12 September 2025,

expected to be broadly neutral for Ryman

•Ryman well progressed to meet new care minute

requirements in Australia in 2026

•The New Zealand Government announced in October

2025 the establishment of a Ministerial Advisory Group to

recommend changes to the aged care funding model

•The independent expert group will provide advice directly

to the Ministers of Health and Seniors, with

recommendations across three key areas:

1.Ensuring sustainable funding

2.Achieving a fair sharing of costs between government

and residents

3.Better integrated aged care with the wider

healthcare system

•Learnings from Australian reforms expected to help shape

new funding model to deliver high quality care with lower

compliance costs (e.g. no care minutes)

•Recommendations due to Ministers mid-2026, prior to the

next election, with the Government targeting changes to

the funding model in 2027

New Australian Aged Care Act takes effect 1 November

1

Commitment to funding reform in New Zealand

1: Funding settings apply to new residents entering aged residential care from 1 November 2025. 2: Indicative annualised benefit will be achieved over several years with average length of stay approximately 18–24 months. Based

on 30 September 2025 Australian RAD balance of $322.5 million (excludes probate balance).

Operations

RYMAN HEALTHCARE | 1H26 Results Presentation17
Development

Kevin Hickman Village

1717

RYMAN HEALTHCARE | 1H26 Results Presentation18
In-flight build programme

Delivery of remaining in-flight projects progressing with sites under active development down from seven to four.

Timing of future stages to be aligned with market demand

Village

Status at

30 September 2025

1H26

completed

2H26

guidance

Under construction

or committed

Future stages

(uncommitted)

Village

Main

building

Remaining

RV stages

RV

units

Care

beds

RV

units

Care

beds

RV

units

Care

beds

RV

units

Care

beds

Nellie Melba

Wheelers Hill

OpenOpenComplete76-------

Deborah Cheetham

Ocean Grove

OpenOpen

Under

construction

6-7---58-

Keith Park

Hobsonville, Auckland

OpenOpen

Under

construction

--64---48-

Kevin Hickman

Christchurch

OpenOpenLand bank7980----76-

Patrick Hogan

Cambridge

Open

Under

construction

Land bank14---606495-

Northwood

Christchurch

Open

Under

construction

Land bank----826032-

Hubert Opperman

1

Mulgrave

OpenPlanningPlanning4---6140--

Total

1798071-203164309-

259

330

FY26 guidance

Development

1: Redesigned plans for Hubert Opperman final stages subject to planning approvals. The updated design figures are reflected in future stage figures (61 RV units and 40 care beds). Refer slide 42 for further detail.

71367309

RYMAN HEALTHCARE | 1H26 Results Presentation
Miriam Corban

Five main buildings opened in past 18 months

RYMAN HEALTHCARE | 1H26 Results Presentation

Village

Main building

opened

Occupancy

1

RV units

2

Care

Miriam Corban

May 202476%76%

James Wattie

June 202470%77%

Keith Park

Aug 202463%78%

Bert Newton

Nov 202472%66%

Kevin Hickman

July 202550%46%

James Wattie

Keith ParkKevin Hickman

Update image

March 24

Bert Newton

Recently opened care centres are filling ahead of expectations, demonstrating strong demand for Ryman’s

high quality aged care offering

1: Occupancy at 30 September 2025. 2: Occupancy of total units including main building and independent stages.

Development

19

RYMAN HEALTHCARE | 1H26 Results Presentation20
Existing village land bank

Developing villages

Deborah Cheetham

Hubert Opperman

Keith Park

Kevin Hickman

Northwood

Patrick Hogan

Mature villages

Grace Joel

Jean Sandel

Murray Halberg

Contracted for sale

Nellie Melba excess land

1

Land bank

1: Held for sale at 30 September 2025. 2: Includes all greenfield land bank sites listed, excluding Karori which was held for sale at balance date but

including other land contracted for sale (Park Terrace & Mt Eliza), plus land at Jean Sandel, Murray Halberg and Deborah Cheetham shown in the

mature village land bank (consistent with presentation in FY25 results).

•$110 million to be released from contracted

property sales:

•$23.0 million for Karori land

1

, settled

subsequent to reporting date

•$9.9 million for excess land at Nellie

Melba

1

, expected to settle in 2H26

•$34.8 million for Mt Eliza, which

contracted in November 2025 and is

expected to settle 2H26

•$42.0 million for Park Terrace, which

contracted in November 2025 and is

expected to settle in FY27

Land bank review well progressed with an update on sites to be retained for future development and divestments

to be provided at investor day

Land bank independent valuation: $376 million

2


Development

Greenfield land bank

Coburg North

Essendon

Karaka

Kealba

Kohimarama

Ringwood East

Rolleston

Takapuna

Taupō

Contracted for sale

Karori

1

Mt Eliza

Park Terrace

RYMAN HEALTHCARE | 1H26 Results Presentation21
Financials

Deborah Cheetham Village

21

RYMAN HEALTHCARE | 1H26 Results Presentation22
Earnings

•Loss before tax and fair value movements (PBTF)

1

improved significantly by $57.6 million, driven by cost-out

programme and stronger performance across mature and developing villages

•Revenue growth of 13% from increasing resident base and occupancy, along with fee growth

Cash flow

•Free cash flow

1

of $56.2 million up $108.7 million due to strong development cash flows and lower financing

costs, partially offset by higher payouts on stock

•Gross interest costs down $28.9 million reflecting lower debt from equity raise and positive free cash flow

Balance sheet

•Balance sheet reset complete with five-year facility tenor plus improved pricing and covenants

•NTA per share of $4.06 down slightly resulting from previously announced restatement, with independent

investment property valuations broadly flat

•Approximately $1.0 billion of unrealised development value including new sales stock, development WIP

and land bank. Includes $110 million of contracted land bank divestments

Metrics

•Refinement of non-GAAP cash flow presentation to better align cash flow with underlying business activity

Financial performance overview

Core operating performance and cash flow trending up, with progressive balance sheet deleveraging

Financials

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding

Ryman's performance. It may not be comparable to similar financial information presented by other entities.

RYMAN HEALTHCARE | 1H26 Results Presentation23RYMAN HEALTHCARE | 1H26 Results Presentation
Key financial metrics

Cash flow from

development activity (CFDA)

1,2

$79.3m

Up $107.4m | 1H25: ($28.1m)

Cash flow from existing

operations (CFEO)

1,2

($23.1m)

Up $1.3m | 1H25: ($24.4m)

Total revenue

2

$413.8m

+13% | 1H25: $366.3m

IFRS profit before tax and fair

value movements (PBTF)

1,2

($43.4m)

Up $57.6m | 1H25: ($101.0m)

Net profit after tax

(NPAT)

2

($45.2m)

-155% | 1H25: $82.0m

NTA per share

406.0 cps

-4.6 cps | March 2025: 410.6 cps

(418.2 cps pre restatement, -12.2cps)

Operating EBITDAF

1,2

$40.1m

+193% | 1H25: $13.7m

Net interest-bearing debt

1,2

$1,651m

-$14m | March 2025: $1,665m

Gearing: 28.5% | March 2025: 28.5%

Free cash flow

1,3

$56.2m

+$108.7m | 1H25: ($52.5m)

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's

performance. It may not be comparable to similar financial information presented by other entities. 2: 1H25 restated due to new accounting policies applied in FY25. 3: Derivative termination costs related to the ITL of $4.8 million

excluded for consistency with free cash flow guidance provided at the time of the equity raise.

Financials

23

RYMAN HEALTHCARE | 1H26 Results Presentation24
99.3

118.7

140.9

160.8

184.0

216.9

2H231H242H241H252H251H26

Revenue

Growing resident base and pricing driving meaningful revenue uplift

Revenue bridge ($m)

•Revenue growth underpinned by care fees,

driven by filling aged care capacity,

government funding uplifts and robust

growth in room premiums

•Growth in resident base of 4% YoY together

with greater weekly fees starting to flow

through revenue

•DMF growth includes benefit from one-off

downward adjustment in 1H25 to fix historic

GST treatment issue

•Revenue uplift from higher contracted DMF

yet to build meaningfully following changes

to DMF recognition accrual periods in FY25

(ILU lifted from 7 years to 9 years and SA

from 3 years to 4.5 years) reflected in the

growth in revenue in advance

1

1: Revenue in advance represents those amounts by which the DMF over

the contractual period exceeds accounting recognition of the DMF based

on expected tenure.

Financials

+47.5

YoY

Revenue in advance balance at period end ($m)

+35%

YoY

366.3

29.7

1.4

4.1

12.2

0.1413.8

1H25

total

revenue

Care

fees

Care

imputed

interest

Village

fees

Deferred

management

fees

Interest and

other income

1H26

total

revenue

350

360

370

380

390

400

410

420

RYMAN HEALTHCARE | 1H26 Results Presentation25
Operating costs

Cost-out initiatives gaining momentum as organisation resets with greater financial discipline

Non-village operating costs ($m)

•Village operating costs up 7%, driven

primarily by capacity growth with five main

buildings opened in the past 18 months

•Gross non-village expenses down 27%

to $54.0 million, driven by cost savings

achieved in FY25 and FY26 YTD across

support and services functions, ongoing shift

to an outsourced development model and

some cost reallocation to village costs

•Non-operating expenses (one-offs) lower

due to significant organisation restructure

costs in 1H25 (consultancy and redundancy)

•Continued focus on annualised cost savings

as a strategic priority

61.6

51.8

49.4

12.3

10.2

4.5

74.0

62.0

54.0

1H252H251H26

ExpensedCapitalised

Financials

-27%

YoY

Operating costs ($m)

1H25

(restated)1H26YoY

Village costs(301.8)(323.9)7%

Gross non-village costs(74.0)(54.0)-27%

Capitalised non-village costs12.34.5-63%

Total operating expenses(363.4)(373.4)3%

Non-operating expenses (one-offs)(10.0)(3.6)-64%

Reported expenses (per P&L)(373.4)(376.9)1%

RYMAN HEALTHCARE | 1H26 Results Presentation26
Improvement in core operating performance

Revenue growth and cost control driving meaningful operating leverage

•Significant uplift in operating EBITDAF

1

,

growing $26.4 million to $40.1 million

•Mature village portfolio (32 villages

2

)

performance increased $4.4 million (9.6%),

supported by revenue growth and cost

efficiencies

•Developing village portfolio (17 villages

2

)

delivered $9.8 million uplift, highlighting

operating leverage to resident growth within

developing villages

•Non-village cost savings of $12.2 million

resulting from new support services

structure and cost-out initiatives

Operating EBITDAF ($m)

1H25

(restated)1H26YoY

Mature villages46.250.610%

Developing villages27.937.735%

Village subtotal74.188.319%

Non-village(60.4)(48.2)-20%

Total13.740.1193%

13.7

4.4

9.8

12.240.1

1H25Mature

villages

Developing

villages

Non-village1H26

-

5

10

15

20

25

30

35

40

45

Operating EBITDAF

1

($m)

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted

Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be

comparable to similar financial information presented by other entities. Refer to note 2 in the FY25 Consolidated Financial Statements for

details of non-operating revenue and expenses. These predominantly relate to one-off costs and provisions associated with employee share

schemes and entitlements, asset write-downs and adjustments reflecting prior period revenue and expenses. 2: Villages are classified as

mature for the purposes of EBITDAF categorisation once fully completed and all accommodation types have maintained at least 90%

occupancy for two consecutive financial years.

Financials

+26.4

YoY

RYMAN HEALTHCARE | 1H26 Results Presentation27
Segmental operating performance

First time segmentation of retirement village and aged care financial performance aligned with FY26 priorities

•Cost allocation methodology aligned with

business activity, fully allocating village and

non-village (support services) costs, with

unallocated non-village costs representing

development and unallocated corporate

costs

•Both aged care and retirement village

segments are currently operating

significantly below their full potential, with a

comprehensive business transformation

underway to improve performance

•Profitability per bed / unit at a group level

will benefit from positive leverage as

developing villages increase in occupancy

and fee / DMF changes flow through the

contract book and P&L

Financials

1H26 Segment performance ($m)Aged care

1

Retirement

village

1

Non-villageGroup

Care and village fees254.7 56.2 - 310.9

Deferred management fees0.2 77.8 - 78.0

Imputed interest income on RADs17.1 - - 17.1

Other income0.5 5.8 1.2 7.5

Operating revenue272.5 139.8 1.2 413.5

Employee expenses(175.6)(46.3)(30.6)(252.5)

Operations(27.4)(12.4)(0.9)(40.7)

Building and grounds(12.3)(36.4)(1.4)(50.1)

Direct selling expenses- (2.1)- (2.1)

Marketing(0.4)(7.7)(2.3)(10.4)

Software and technology(0.1)(0.4)(9.0)(9.5)

Administration(0.8)(2.0)(9.8)(12.6)

Gross operating expenses(216.6)(107.3)(54.0)(377.9)

Support services allocation(22.7)(13.7)36.4 -

Capitalised costs- - 4.5 4.5

Segmented operating expenses(239.3)(121.0)(13.1)(373.4)

Operating EBITDAF33.218.8 (11.9)40.1

Per bed/unit per year ($000s, annualised)

Operating revenue126.132.5

Segmented operating expenses(110.8)(28.1)

EBITDAF per bed/unit per year15.34.4

Operating margin12%13%

1: Aged care and retirement village activities are not considered operating segments under NZ IFRS 8 – Operating Segments. These activities are

not reported separately in the 1H26 Consolidated Interim Financial Statements, as their financial information is not regularly reviewed by the Chief

Operating Decision Maker (CODM) for purposes of resource allocation or performance assessment.

RYMAN HEALTHCARE | 1H26 Results Presentation28
Cash flow from existing operations (CFEO)

Robust cash flow from village operations offset by increased bought back stock on hand

•Cash flow from village operations up 63% to

$36.4 million reflecting fee growth and cost

control across both expenses and capex

•Net cash flow from resales includes

$53.0 million impact from increase in unit

payout balance (bought back stock)

•$9.9 million improvement in non-village

cash flow reflecting cost initiatives

•Reduction in net interest attributed to CFEO

1


driven by savings from equity raise and

allocation of interest to CFDA

Updated CFEO calculation

•Notional interest on new stock and land

bank (expensed under IFRS) allocated to

CFDA. 1H25 not restated

•Marketing expenses allocated across resales

(included in cash flow from resales in ORAs)

and new sales (moved to CFDA for both

periods)

$m

1H25

restated1H26YoY $

Village operations

Care and village fees284.1317.032.9

DMF collected41.442.91.5

Payments to suppliers and employees(282.4)(307.9)(25.6)

Village capex(17.4)(13.3)4.0

Capex on technology projects(3.4)(2.3)1.1

Subtotal village operations22.436.413.9

Resales of ORAs

Resales settlements of occupation rights407.9362.0(46.0)

Repayment of occupation rights(272.8)(287.6)(14.7)

Gross receipts from resales135.174.4(60.7)

Less DMF collected (included in village operations)(41.4)(42.9)(1.5)

Net resales receipts93.731.5(62.2)

Capex on RV unit refurbishments(16.4)(13.6)2.8

Sales and marketing expenses - resales(13.7)(10.9)2.8

Subtotal resales of ORAs63.57.0(56.5)

Total village cash flow86.043.3(42.6)

Non-village cash flow

Payments to suppliers and employees(60.2)(50.6)9.5

Capex on head office and other projects(4.9)(1.3)3.6

Office leases(2.1)(1.3)0.8

Employee share schemes4.60.5(4.1)

Total non-village cash flow(62.6)(52.7)9.9

Cash flow from existing operations pre interest23.4(9.4)(32.8)

Expensed interest(48.9)(36.6)12.3

Notional interest on new unit stock and land bank-22.522.5

Interest received1.20.3(0.8)

Net interest attributed to CFEO(47.7)(13.7)34.0

Cash flow from existing operations (CFEO)(24.4)(23.1)1.3

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting

Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be comparable to similar

financial information presented by other entities.

Financials

RYMAN HEALTHCARE | 1H26 Results Presentation29
Cash flow from development activity (CFDA)

Strong cash release as development investment scales back

•Significant reduction in development

spend reflecting fewer sites under active

construction and lower spend on high

density projects and main buildings

•Resident funding from new sales down less

than development capex, driving

meaningful net cash uplift in CFDA

1

•Significant cash opportunity lies in new sales

stock balance of 592 units, with value of

approximately $470 million

•Lower sales and marketing spend driven by

incentive type mix, with higher costs

expected in 2H26

Updated CFDA calculation

•Notional interest on new stock and land

bank (expensed under IFRS) allocated to

CFDA. 1H25 not restated

•Marketing expenses allocated to new sales

(CFDA) in 1H26 and prior period

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting

Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be comparable to similar

financial information presented by other entities. 2: Net increase in RADS is driven predominantly by new RADS and has therefore been classified

to development activity for simplicity. 3: Land acquisitions reflect land purchased in prior periods with full or partial deferred settlements. 4: Land

and asset sales in 1H26 reflect sale of construction property, plant and equipment (1H25: Newtown settlement).

Financials

$m

1H25

(restated)1H26YoY

Resident funding

New sale settlements of occupation rights203.8168.0(35.7)

Net increase in RADs on aged care beds

2

51.432.9(18.6)

Sales and marketing expenses - new sales(9.4)(5.7)3.6

Subtotal resident funding245.8195.2(50.6)

Development capex

Land acquisitions

3

(18.3)(2.0)16.3

Direct construction capex(220.1)(76.2)143.9

Capitalised interest(31.6)(8.8)22.8

Non-village expenses capitalised to projects(11.1)(4.5)6.5

Subtotal development capex(281.1)(91.6)189.5

Other development cash flows

Notional interest on new unit stock and land bank-(22.5)(22.5)

Land bank expenses-(3.2)(3.2)

Proceeds from land and asset sales

4

7.11.4(5.7)

Subtotal other development cash flow7.1(24.3)(31.4)

Cash flow from development activity(28.1)79.3107.4

RYMAN HEALTHCARE | 1H26 Results Presentation30
(68.8)

(61.5)

(201.6)

(131.6)

(158.2)

(270.5)

(436.3)

(206.8)

(389.6)

(186.9)

(94.2)

56.2

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY251H26

Free cash flow

First positive free cash flow result in over a decade of $56.2 million with demonstrated progress to operational reset

Free cash flow

1

($m)

•Material growth in free cash flow

1

of

$108.7 million YoY from -$52.5 million in 1H25

to $56.2 million in 1H26

•Uplift driven by development activity, with

existing operations steady on 1H25

•Cash interest cost savings of $35.1 million on

1H25 reflected in both CFEO and CFDA

•Net debt reduced $14.1 million with

$56.2 million impact of free cash flow

offset by FX translation impact of AUD debt

($36.7 million), derivative termination costs

relating to the ITL ($4.8 million) and minor

financing movements

•Targeting of continued growth in free cash

flow remains an operational focus

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting

Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be comparable to similar

financial information presented by other entities.

Financials

Net debt

1

movement ($m)

1,664.9

42.1

23.1

-79.3

1,650.8

Mar-25FX and otherCFEOCFDASep-25

1,600

1,620

1,640

1,660

1,680

1,700

1,720

1,740

Free cash flow

$56.2 million

-14.1

HoH

RYMAN HEALTHCARE | 1H26 Results Presentation31
10,813

(77)

10,736

80

95

15

(11)

(1)

10,914

Mar-25

balance

(reported)

Adjustment:

suspended

contributions

Mar-25

balance

(restated)

FX on

Mar-25

balance

AdditionsFV mov'

existing

units

FV mov'

new

units

FV mov'

land

bank

Sep-25

balance

10,600

10,650

10,700

10,750

10,800

10,850

10,900

10,950

11,000

Asset valuations

Underlying fair value movements broadly flat despite challenging market conditions

Investment property carrying value ($m)

•Valuation outcome for existing units broadly

flat, with valuer assumptions for unit pricing

down modestly, partially offset by higher

year one growth rates which reflects

improving market outlook and embedding

of 2H25 pricing model changes

•Fair value movements on developing

villages and land bank broadly flat

•Previously disclosed

1

-$77 million impact

from historical issue relating to NZ IAS 40

adjustments due to a change in valuation

approach at March 2025 where a subset of

suspended contributions were included in

the independent valuation

•Care centres not valued at half year.

Small impairment in property, plant and

equipment ($2.4 million) reflecting three

care centres

3

Financials

Total fair value movement

$3.2 million

1: Refer slide 5 in the 2025 Governance Presentation (link). 2: Impact on Mar-25 AUD investment property balance of $2,004 million

from NZD/AUD declining from 0.9088 at March 2025 to 0.8771 at September 2025. 3: Includes fair value movement at villages with unit

deliveries in 1H26.

2

RYMAN HEALTHCARE | 1H26 Results Presentation32
Reported profit and loss

Improvement in operating earnings offset by lower fair value movements

1: Ryman reviewed the assumption for expected resident tenure relating to DMF revenue recognition in FY25, with accrual period assumptions

increased from 7 years to 9 years for independent units and 3 years to 4.5 years for serviced apartments from 1 April 2025.Change to revenue

recognition made on a go-forward basis, with no change to historic accruals. 2: GST adjustment and uncapped internal transfers related to

prior periods. 3: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally

Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be

comparable to similar financial information presented by other entities.

•Total revenue increased 13%, with growth in

both pricing and utilisation, while total costs

fell 2%

•DMF revenue excluding historic adjustments

flat YoY driven by changes to accrual

periods in FY25

1

and new higher DMF

contracts only just starting to contribute

•Profit/(loss) before tax and fair value

movements (PBTF) improved to -$43.4 million

from -$101.0 million last year, driven by

strong operating leverage

•Deferred tax expense lower as the prior

period included the impact of moving to

a 30% standard DMF on expected future

taxable income

•Earnings per share of -4.4cps, reduced as a

result of fair value movements from property

revaluations and more shares on issue after

the February 2025 equity raise

Financials

Profit and loss ($m)

1H25

(restated)1H26YoY

Care and village fees277.0310.912%

Deferred management fees (DMF) exc. historical adjustments77.878.00%

Historical adjustments to DMF

2

(12.0)--100%

Imputed income on RADs15.717.19%

Other income6.67.513%

Interest received1.10.3-72%

Total revenue366.3413.813%

Operating expenses(373.4)(376.9)1%

Depreciation and amortisation expenses(24.9)(21.8)-13%

Imputed income charge on RADs(15.7)(17.1)9%

Impairment loss-(2.4)n/a

Finance costs(53.2)(39.0)-27%

Total expenses(467.3)(457.2)-2%

Profit/(loss) before tax and fair value movements (PBTF)

3

(101.0)(43.4)-57%

Fair value movement of investment properties270.13.2-99%

Deferred tax credit/(expense)(87.1)(5.0)-94%

Net profit after tax (NPAT)82.0(45.2)-155%

Per share:

Weighted shares on issue (000s)687.61,015.748%

PBTF per share (cps)(14.7)(4.3)-71%

Earnings per share (cps)11.9(4.4)-137%

RYMAN HEALTHCARE | 1H26 Results Presentation33
Raelene Boyle Village resident Brian in the village workshop

33

Capital management

RYMAN HEALTHCARE | 1H26 Results Presentation34
Full bank debt refinance

Balance sheet reset complete with new funding structure aligned with operating model

•Full refinancing of $2 billion syndicated loan

facilities completed on 24 November 2025,

extending weighted term to maturity

1

to

4.8 years with no bank facility maturities

until FY31

•Improved pricing on margins and line fees

•Interest Cover Ratio (ICR) covenant

2


of 1.50x commencing from September 2026

(existing covenant waiver remains for

September 2025 and March 2026)

•No change to other financial covenants,

with the adjusted total liabilities to net

tangible assets maximum permitted ratio

remaining at 1.0x

•ICR covenant excludes interest on

designated development debt

3


($687 million at 30 September 2025)

•$535 million of debt headroom

1

Capital management

Debt facility maturity profile ($m)

Debt facilities ($m)Sep 25

Sep 25

pro-forma

1

NZD & AUD bank facilities2,0892,048

NZD retail bond150150

Total facilities at face value2,2392,198

Drawn debt at face value1,6631,663

Debt headroom576535

Average term to expiry2.14.8

1: Pro-forma at 30 September including impact from refinancing which occurred on 24 November 2025. 2: Rolling 12-month adjusted EBITDA to

interest (excluding interest on development debt) tested on 31 March and 30 September. Adjusted EBITDA is defined as reported net profit after

tax, adjusted by excluding income tax, interest income, finance costs, depreciation, amortisation, impairment losses, fair value movements,

deferred management fees, and one-off revenue and expenses, and including non-GAAP items: cash deferred management fees collected, and

gross resale gains on occupation right agreements. 3: Based on forecast net cash proceeds for committed developments and the cost of New

Zealand care centres under development or opened in the past 24 months. Development debt for new projects is included once lenders approve

the Company’s feasibility and substantive steps towards the development have commenced.

710

507

578

444

150

524

246

75

798

353

51

1,322

599

126

FY26FY27FY28FY29FY30FY31FY32FY33

Prior debt facilitiesRetail BondBank debt (NZ)Bank debt (AU)

RYMAN HEALTHCARE | 1H26 Results Presentation35
162

-67

95

Pre February 2025

equity raise

Impact of equity raise

and bank refinance

Current run rate

(pro-forma)

Treasury management

Annualised interest savings of $67 million reflecting equity raise and lower borrowing costs

•Weighted average cost on total drawn debt

(WACD)

1

of 5.70%, down ~50bps driven by

improved bank pricing on bank loans and

lower floating rates

•68% of drawn debt at September 2025 is

on fixed rates. Average hedging tenor of

3.2 years provides interest cost certainty

•Annual interest savings of $67 million since

February 2025 equity raise reflects combined

impacts of lower drawn debt and lower

WACD

Capital management

1: At 30 September including impact from refinancing which occurred on 24 November 2025.

Key treasury metricsMar 25

Sep 25

pro-forma

1

Total drawn debt ($m)1,6861,663

Total active fixed rate debt ($m)1,1381,127

Percentage of drawn debt at fixed rates67%68%

Weighted average term of fixed rate debt3.6 years3.2 years

Weighted average cost on total drawn debt (WACD)6.2%5.7%

Annualised gross interest costs ($m)

1

RYMAN HEALTHCARE | 1H26 Results Presentation36
Outlook and strategic

priorities

Edmund Hillary Village resident Margaret and caregiver Heather

3636

RYMAN HEALTHCARE | 1H26 Results Presentation37
FY26 Outlook

Strong first half progress supports upgraded FY26 guidance, with continuing mixed market conditions expected in

the second half

•2H26 sales expected to be broadly in line

with 1H26 amidst mixed market conditions

and lower new sales expected on the back

of fewer 2H unit deliveries vs 1H

•Expect ongoing variability as local property

markets recover at differing speeds –

Victoria recovering, mixed across regions

throughout New Zealand with Auckland yet

to show meaningful improvement (~30% of

portfolio in Auckland by volume)

•Lower cost structures in support services and

village cost efficiencies driving uplift in

annualised cost-out target from $46 million

(previous guidance) to $50–60 million

•Capex

1

guidance moderated, including

release of project contingency for

completed developments, and disciplined

approach to sustaining capex for existing

operations

Sales of ORAs

1


(occupation basis)

1,300–1,400 at higher DMF / FY25: 1,523

(previous guidance: 1,100–1,300)

Annualised cost

savings

2

Annualised cost saving target increased to $50–60 million /

FY25: $23 million (previous guidance: $46 million)

Build rate 330 including 80 care beds and 250 RV units / FY25: 950

(previous guidance: 266–330)

Capex

2,3

$235–265 million / FY25: $535.3 million, including:

(previous guidance: $260–320 million)

•$170–190 million development / FY25: $458.2 million

(previous guidance: $180–230 million)

•$65–75 million existing operations / FY25: $77.1 million

(previous guidance: $80–90 million)

FY26 Guidance

Based on current environment and assessment of future trends

1: Reported sales figures reflect retirement village units only and exclude refundable accommodation deposits (RADs) and ORAs on aged care

accommodation. 2: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally

Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding Ryman's performance. It may not be

comparable to similar financial information presented by other entities. 3: Net investing cash flows as presented in the Consolidated Financial

Statements, excluding proceeds from land and asset sales and receipts or advances of employee loans (combined 1H26 exclusions: $1.4

million). Refer appendix 16 for breakdown.

Outlook

RYMAN HEALTHCARE | 1H26 Results Presentation38
FY26 priorities First half update

Building sales effectiveness to release cash from RV

unit stock

Significant cash release from new development

Recovering resales momentum; focus on rebuilding sales

to match turnover

Care ORAs in New Zealand to grow resident capital

in care

‘Resident Fund’ product to facilitate capital transfer into

care successfully trialled, now being rolled out across NZ

portfolio

Divestment programme for selected land bank sitesPark Terrace & Mt Eliza land sales contracted for $77

million; progressively working through review of other sites

Continue to build sales effectiveness, increasing

number of units on new contract terms

Achieved 28.8% average DMF across 1H26 sales.

7% lift in average weekly fees vs pcp

Targeting doubling of annualised cost savings to

$46 million

$40 million achieved; FY26 target lifted to $50–60 million

NZ care funding reforms & review of aged care

capacity

NZ Government targeting funding changes in 2027;

Planned closure of two underperforming care centres

Organisation-wide performance cadence, including

segmentation of care/RV reporting

Performance cadence established organisation wide,

now moving to future redesign. Initial segmentation of

care/RV reporting complete

Portfolio and strategy review to identify best

opportunities to optimise and grow

Strategy and capital management review progressing

with update to be provided at investor day

Align design with future development opportunities in

existing villages and land bank

Capital management framework aligned

to strategy & plans for growth

Update on strategic priorities

Meaningful progress achieved against FY26 priorities

1: Includes both revenue and cost opportunities.

Outlook

1. Release cash from the business

Target over $500m in the next 3–5 years

2. Sustainable business improvement

Target $100–150m annualised cash

improvement

1

over 3–5 years

3. Disciplined approach to growth

Target lower peak capital intensity and

increased flexibility

RYMAN HEALTHCARE | 1H26 Results Presentation39
Closing remarks

1

Near-term focus remains on continuing to build sales

momentum, releasing cash from the business and

driving operational efficiencies

2

Ryman is well positioned for cash flow growth with

significant leverage to a housing cycle rebound, NZ

aged care funding reforms and the strengthening

demographic tailwinds from an ageing population

and growing scarcity of quality care

3

Investor day planned for 3 February 2026

•Strategy refresh

•Growing earnings of the existing business

•Focused growth opportunities with disciplined

execution

•New capital management framework and

dividend policy

Outlook

Edmund Hillary Village resident Peter and family

39

RYMAN HEALTHCARE | 1H26 Results Presentation40
Q&A

Bruce McLaren Village resident Margaret and caregiver Priya

40

RYMAN HEALTHCARE | 1H26 Results Presentation41
Kevin Hickman Village

41

Development updates

RYMAN HEALTHCARE | 1H26 Results Presentation42
Development progress summary

TH = independent townhouse, IA= independent apartment, SA = serviced apartment

Appendices

CategoryVillageStageTHIASA

Total RV

units

Aged care

beds

Total units

and beds

1H26 build

Kevin HickmanStage 1 (main building)

-14657980159

Deborah CheethamStage 11a

6--6-6

Nellie MelbaStage 4

-76-76-76

Hubert OppermanStage 6

4--4-4

Patrick HoganStage 7

14--14-14

Subtotal

24906517980259

2H26 build

Deborah CheethamStage 11b

7--7-7

Keith ParkStage 8

-40-40-40

Keith ParkStage 9

-24-24-24

Subtotal

764-71-71

Under construction

or committed

Patrick HoganStage 1 (main building)

--606064124

NorthwoodStage 1 (main building)

-11718260142

Hubert OppermanVarious (inc. main building)

2932-6140101

Subtotal

2943131203164367

Future stages

Deborah CheethamVarious

58--58-58

Keith ParkVarious

-48-48-48

Kevin HickmanVarious

868-76-76

NorthwoodVarious

1418-32-32

Patrick HoganVarious

95--95-95

Subtotal

175134-309-309

Total

2353311967622441,006

RYMAN HEALTHCARE | 1H26 Results Presentation43
Development progress

For the 6 months to 30 September 2025

Keith Park

Hobsonville, Auckland

Townhouse: 0 | Apartment: 276 | Serviced: 101 | Care: 120

•Stage 8 under construction (40 apartments)

•Stage 9 under construction (24 apartments)

•Future stages in land bank

Opened: June 2021

Status: under construction

Photo, 17 September 2025

Stage 8

Stage 9

Patrick Hogan

Cambridge

Townhouse: 185 | Apartment: 0 | Serviced: 60 | Care: 64

•Stage 7 completed in May 2025 (14 townhouses)

•Main building commenced construction in 1H26 (60 serviced, 64 care)

•Future stages in land bank

Opened: July 2023

Status: under construction

Stage 7

Photo, 19 September 2025

Main building

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation44
Development progress

Northwood

Christchurch

Townhouse: 82 | Apartment: 83 | Serviced: 71 | Care: 60

•Main building under construction (11 apartments, 71 serviced, 60 care)

•Future stages in land bank

Kevin Hickman

Riccarton Park, Christchurch

Townhouse: 59 | Apartment: 172 | Serviced: 65 | Care: 80

•Main building opened July 2025 (14 apartments, 65 serviced, 80 care)

•Future stages in land bank

Photo, February 2024Photo, February 2024Photo, February 2024

Photo, 18 September 2025Photo, 15 September 2025

For the 6 months to 30 September 2025

Opened: June 2021

Status: land bank

Opened: June 2023

Status: under construction

Main building

Main building

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation45
Development progress

Deborah Cheetham

Ocean Grove

Townhouse: 203 | Apartment: 0 | Serviced: 53 | Care: 120

•Stage 11a completed in June 2025 (6 townhouses)

•Stage 11b under construction (7 townhouses)

•Future stages in land bank

Hubert Opperman

Mulgrave, Melbourne

Townhouse: 80 | Apartment: 32 | Serviced: 0 | Care: 40

•Stage 6 completed in April 2025 (4 townhouses)

•Future stages redesigned to reduce capital intensity and optimise unit mix to

better meet market demand (29 townhouses, 32 apartments, 40 care).

Redesigned subject to planning approvals

Photo, February 2024Photo, February 2024Photo, February 2024

Photo, March 2024

Photo, March 2024

Photo, March 2024

Photo, 29 September 2025Photo, 24 September 2025

For the 6 months to 30 September 2025

Opened: August 2024

Status: planning

Opened: December 2020

Status: under construction

Stage 6

Stage 11a

Stage 11b

Stage 11a

Appendices

Stage 11b

RYMAN HEALTHCARE | 1H26 Results Presentation46
Stage 4

Development progress

Nellie Melba

Wheelers Hill, Melbourne

Townhouse: 0 | Apartment: 332 | Serviced: 85 | Care: 190

•Stage 4 apartments (final stage) completed in July 2025 (76 apartments)

Photo, 27 October 2025

For the 6 months to 30 September 2025

Opened: August 2018

Status: Complete

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation47
Deborah Cheetham Village resident Joy and daughter Alison

47

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation48
Appendix 1: Half year metrics

1H252H251H26

RV unit occupancy

Occupied8,4198,5388,621

Unoccupied1,1561,2391,335

Occupancy (%)87.9%87.3%86.6%

Occupancy (%) - mature93.8%92.8%91.8%

Units paid out (#)271358426

Payout balance ($m)$156.1$223.5$276.5

Aged care

Mature care centres373736

Developing care centres779

Total operational care centres444445

Occupancy (%)91.6%90.2%91.1%

Occupancy - mature (%)96.4%96.3%96.1%

Residents

Total residents15,08515,15615,312

Average age on entry – independent79.979.680.4

Average age on entry – serviced86.385.785.7

Average age on entry - aged care84.985.384.8

Average age current - independent82.483.182.7

Average age current - serviced87.387.987.3

Average age current - aged care86.286.885.8

1: Villages are classified open when the first stage is completed. 2: Includes villages which are open and yet to be completed. 3: Excludes sites held for sale at balance date or subsequently contracted for sale post balance date

prior to reporting date.

RYMAN HEALTHCARE | 1H26 Results Presentation

Appendices

1H252H251H26

Villages

Open

1

494949

Under active construction

2

974

Land bank

3

10119

Land held for sale or contracted for sale213

Portfolio

RV units9,5759,7779,956

Aged care beds4,6194,7004,781

Total14,19414,47714,737

Build rate (completed)

RV units387204179

Aged care beds2808080

Total667284259

RV unit sales

New sales of ORAs224192166

Resales of ORAs603504538

Total sales of ORAs827696704

Vacated units628572619

Turnover (% portfolio, annualised)13.1%11.7%12.4%

48

RYMAN HEALTHCARE | 1H26 Results Presentation49
Appendix 2: Ryman Board and Management

Dean Hamilton

CHAIR

Joined: June 2023

Scott Pritchard

NON-EXECUTIVE DIRECTOR

Joined: November 2024

James Miller

NON-EXECUTIVE DIRECTOR

Joined: June 2023

Kate Munnings

NON-EXECUTIVE DIRECTOR

Joined: November 2023

David Pitman

NON-EXECUTIVE DIRECTOR

Joined: May 2024

Naomi James

CHIEF EXECUTIVE

OFFICER

Joined: November 2024

Marsha Cadman

CHIEF OPERATING

OFFICER

Rejoined: January 2024

Rick Davies

CHIEF CUSTOMER AND

TECHNOLOGY OFFICER

Joined: July 2019

Di Walsh

CHIEF PEOPLE

AND SAFETY OFFICER

Joined: January 2023

BoardExecutive team

Paula Jeffs

NON-EXECUTIVE DIRECTOR

Joined: November 2019

Marie Bonnemaison

CHIEF STRATEGY AND

CORPORATE DEVELOPMENT

OFFICER

Joined: January 2025

Paul Blackler

ACTING CHIEF DEVELOPMENT

AND PROPERTY OFFICER

Joined: July 2019

Commenced in role: August 2025

Matt Prior

CHIEF FINANCIAL

OFFICER

Joined: July 2025

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation50
Appendix 3: Sales of ORAs

New sales

1

Volume

(#)

Gross value

($000s)

Average ORA price

($000s)

1H251H26YoY1H251H26YoY1H251H26YoY

IndependentNZ12571-43%119,05262,491-48%952880-8%

AU446036%55,79780,59644%1,2681,3436%

Group169131-22%174,849143,087-18%1,0351,0926%

ServicedNZ3120-35%21,22312,204-42%685610-11%

AU2415-38%18,68611,901-36%7797932%

Group5535-36%39,90824,105-40%726689-5%

All unitsNZ15691-42%140,27574,695-47%899821-9%

AU687510%74,48292,49724%1,0951,23313%

Group224166-26%214,757167,192-22%9591,0075%

Resales

1

Volume

(#)

Gross value

($000s)

Average ORA price

($000s)

Gross margin

($000s)

Gross margin

(% price)

1H251H26YoY1H251H26YoY1H251H26YoY1H251H26YoY1H251H26YoY

IndependentNZ242221-9%211,765187,381-12%875848-3%79,66756,316-29%37.6%30.1%-7.6%

AU3631-14%37,11332,911-11%1,0311,0623%4,7953,930-18%12.9%11.9%-1.0%

Group278252-9%248,878220,293-11%895874-2%84,46260,246-29%33.9%27.3%-6.6%

ServicedNZ292255-13%162,878144,193-11%5585651%28,88116,962-41%17.7%11.8%-6.0%

AU3331-6%24,93523,505-6%7567580%2,6341,566-41%10.6%6.7%-3.9%

Group325286-12%187,813167,697-11%5785861%31,51518,528-41%16.8%11.0%-5.7%

All unitsNZ534476-11%374,643331,574-11%702697-1%108,54773,278-32%29.0%22.1%-6.9%

AU6962-10%62,04956,416-9%8999101%7,4305,496-26%12.0%9.7%-2.2%

Group603538-11%436,692387,990-11%724721-0%115,97778,774-32%26.6%20.3%-6.3%

Total827704-15%651,449555,182-15%7887890%

1: Reported sales figures reflect retirement village units only and exclude refundable accommodation deposits (RADs) and ORAs on aged care accommodation. Note: Gross development margins are not included in this table

(shown in previous results presentations) as the these are no longer reported by the Group.

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation51
RV unit stockSep-24Mar-25Sep-25

All units

Asset base (completed units)9,5759,7779,956

Total occupied units8,4198,5388,621

% asset base87.9%87.3%86.6%

Total unoccupied units1,1561,2391,335

% asset base12.1%12.7%13.4%

Total contracted units522367380

% asset base5.5%3.8%3.8%

Total uncontracted units634872955

% asset base6.6%8.9%9.6%

New sales stock

Contracted units185104124

Uncontracted units379474468

Total unoccupied new sale units564578592

Resales stock

Contracted units337263256

Uncontracted units255398487

Total unoccupied resale units592661743

Total stock

Contracted units522367380

Uncontracted units634872955

Total unoccupied units1,1561,2391,335

Appendices

Appendix 4: Retirement village unit stock

RYMAN HEALTHCARE | 1H26 Results Presentation52
Appendix 5: Asset base and land bank

TH = independent townhouse, IA= independent apartment, SA = serviced apartment, Res = rest home care bed, Hos = hospital care bed, Dem = dementia care bed

Appendices

New Zealand

VillageLocationOpenedTHIASAResHosDem

Asset

baseTHIASAResHosDem

Land

bankTotal

WoodcoteChristchurchFY9118-748--73-------73

Essie SummersChristchurchFY9222-58304124175-------175

Margaret StoddartChristchurchFY9420-1947--86-------86

Frances HodgkinsDunedinFY95-423250--124-------124

Rowena JacksonInvercargillFY97103-46596332303-------303

Malvina MajorWellingtonFY99-123395858-278-------278

Ngaio MarshChristchurchFY99119-404172-272-------272

Shona McFarlaneWellingtonFY01130-503840-258-------258

Rita AngusWellingtonFY02-99492049-217-------217

Hilda RossHamiltonFY02167-51426940369-------369

Grace JoelAucklandFY034232652771-237-96----96333

Princess AlexandraNapierFY04551754246024234-------234

Jane WinstoneWhanganuiFY0654-50242520173-------173

Anthony WildingChristchurchFY07110-50358033308-------308

Julia WallacePalmerston NorthFY07111-50283521245-------245

Edmund HillaryAucklandFY0890282605011430626-------626

Ernest RutherfordNelsonFY081002475274225293-------293

Jean SandelNew PlymouthFY0914427603950223424514----59401

Jane ManderWhangāreiFY101156871206032366-------366

Evelyn PageAucklandFY103621263206037428-------428

Kiri Te KanawaGisborneFY11842161414016263-------263

Yvette WilliamsDunedinFY11--3235728120-------120

Bob OwensTaurangaFY1210511379404040417-------417

Diana IsaacChristchurchFY122332379404040455-------455

Charles FlemingWaikanaeFY131386379404040400-------400

Bruce McLarenAucklandFY15-19472404141388-------388

Possum BourneAucklandFY162174284404040463-------463

Bob ScottWellingtonFY16-25489344040457-------457

Charles UphamRangioraFY161986687404040471-------471

Bert SutcliffeAucklandFY17-22581404038424-------424

Logan CampbellAucklandFY18-11680434330312-------312

Murray HalbergAucklandFY19-22886424238436-116----116552

William SandersAucklandFY20-18977383836378-------378

Linda JonesHamiltonFY209115793404036457-------457

Miriam CorbanAucklandFY213217666202031345-------345

James WattieHavelock NorthFY211034478353520315-------315

Keith ParkAucklandFY22-164101404040385-112----112497

Kevin HickmanChristchurchFY225110465402020300868----76376

NorthwoodChristchurchFY246854----122142971151530174296

Patrick HoganCambridgeFY2490-----9095-60171730219309

TakapunaAuckland--------5930151515134134

KarakaAuckland-------1426460171734334334

TaupōWaikato-------203-64141428323323

RollestonRolleston-------218-64181836354354

Subtotal2,8463,1592,3781,3831,68595412,40572555834996961731,99714,402

RYMAN HEALTHCARE | 1H26 Results Presentation53
Appendix 5: Asset base and land bank cont.

TH = independent townhouse, IA= independent apartment, SA = serviced apartment, Res = rest home care bed, Hos = hospital care bed, Dem = dementia care bed

Appendices

1: Hubert Opperman and Northwood. 2: Park Terrace and Mt Eliza

Australia

VillageLocationOpenedTHIASAResHosDemAsset

base

THIASAResHosDemLand

bank

Total

Weary DunlopMelbourneFY15-20048204220330-------330

Charles BrownlowGeelongFY21572360404020240-------240

Essendon TerraceMelbourneFY22-36----36-------36

John FlynnMelbourneFY21-17495393936383-------383

Raelene BoyleMelbourneFY22-6427193718165-------165

Nellie MelbaMelbourneFY19-33285777736607-------607

Deborah CheethamOcean GroveFY21138-5340404031165-----65376

Bert NewtonMelbourneFY24-8545303019209-------209

Hubert OppermanMelbourneFY2551-----512932--40-101152

Ringwood EastMelbourne--------23779202040396396

Coburg NorthMelbourne--------33265-6420481481

EssendonMelbourne--------16250-3030272272

KealbaMelbourne-------1403331202020264264

Subtotal2469144132653051892,332234796225401741101,5793,911

Total portfolio

VillageTHIASAResHosDemAsset

base

THIASAResHosDemLand

bank

Total

Australia2469144132653051892,332234796225401741101,5793,911

New Zealand2,8463,1592,3781,3831,68595412,40572555834996961731,99714,402

Total3,0924,0732,7911,6481,9901,14314,7379591,3545741362702833,57618,313

1H26 movement

VillageTHIASAResHosDemAsset

base

THIASAResHosDemLand

bank

Total

31 March 2025 reported3,0683,9832,7261,6081,9701,12214,4779731,7677471763414174,42118,898

Build rate (new development)249065402020259(24)(90)(65)(40)(20)(20)(259)-

Reconfigurations (existing units)-----11-------1

Redesign of land bank villages-------10(73)(54)2010(54)(141)(141)

Villages removed from land bank--------(250)(54)(20)(61)(60)(445)(445)

30 September 20253,0924,0732,7911,6481,9901,14314,7379591,3545741362702833,57618,313

RYMAN HEALTHCARE | 1H26 Results Presentation54
Appendix 6: Investment property valuation

Independent valuation assumptions

31 March 2025Valuer unit price inflation assumption

Discount

rate

Yr 1Yr 2Yr 3Yr 4Yr 5+

Auckland0.6%1.7%2.4%2.9%3.4%13.6%

Rest of New Zealand0.7%1.8%2.3%2.8%3.4%14.0%

Australia1.7%2.0%2.0%2.0%2.6%13.2%

30 September 2025Valuer unit price inflation assumption

Discount

rate

Yr 1Yr 2Yr 3Yr 4Yr 5+

Auckland1.4%1.9%2.4%3.0%3.5%13.6%

Rest of New Zealand1.4%1.9%2.4%2.9%3.4%14.0%

Australia1.8%2.0%2.0%2.0%2.6%13.2%

Retirement village units included in independent valuation

Mar-25Sep-25

Currently occupied, and vacant not repaid units

8,8988,996

Completed new units not occupied, and repaid resale units

881962

Total units9,7799,958

Appendices

Investment property reconciliation ($m)

Mar-25

(restated)

Sep-25

Subject to independent valuation

Operators interest3,973 4,084

Completed new units not occupied, and repaid resale units617 657

Development land – land bank369 376

Development land – construction sites64 63

Commercial property16 17

Held at cost

Work in progress – construction WIP283 150

Adjustments

Revenue in advance184 217

Gross occupancy advance6,167 6,410

Accrued DMF(830)(904)

Suspended contributions(77)(128)

Occupancy advance adjustments(30)(27)

Total investment property10,736 10,914

Breakdown of total investment property ($m)

Land

Work in

progress

Completed

propertySep-25

Balance 31 March 2025 - reported43328310,09610,813

Restatements--(77)(77)

Balance 31 March 2025 - restated43328310,01910,736

Additions (capex)(0)761995

Land acquired----

Land transferred to held for sale----

Land transferred to WIP(1)1--

WIP transferred to complete-(214)214-

Fair value movement(1)-43

FX movement846880

Balance 30 September 202543915010,32510,914

RYMAN HEALTHCARE | 1H26 Results Presentation55
Appendix 7: Investment property valuation – key assumptions

Appendices

New Zealand villages

VillageLocationUnitsValuation ($m)Discount rateGrowth rate Yr 1Growth rate Yr 2Growth rate Yr 3Growth rate Yr 4Growth rate Yr 5+

Jane Mander Retirement VillageWhangarei25420914.5%1.3%1.8%2.3%2.7%3.5%

Evelyn Page Retirement VillageAuckland31137313.5%1.4%1.9%2.5%3.0%3.5%

Bert Sutcliffe Retirement VillageAuckland30635213.5%1.4%1.9%2.4%3.0%3.5%

William Sanders Retirement VillageAuckland26641814.0%1.4%1.9%2.4%3.0%3.5%

Keith Park Retirement VillageAuckland26528214.3%1.1%1.5%2.3%2.8%3.5%

Edmund Hillary Retirement VillageAuckland43263413.5%1.4%1.9%2.5%3.0%3.5%

Grace Joel Retirement VillageAuckland13927613.3%1.3%1.8%2.5%3.0%3.5%

Bruce McLaren Retirement VillageAuckland26631913.0%1.4%1.9%2.5%3.0%3.5%

Logan Campbell Retirement VillageAuckland19626813.8%1.3%1.8%2.3%3.0%3.5%

Miriam Corban Retirement VillageAuckland27428714.3%1.4%1.9%2.5%3.0%3.5%

Murray Halberg Retirement VillageAuckland31431413.8%1.4%1.9%2.5%3.0%3.5%

Possum Bourne Retirement VillageAuckland34337713.5%1.4%1.9%2.4%3.0%3.5%

Hilda Ross Retirement VillageHamilton21818314.0%1.4%1.9%2.4%3.0%3.5%

Linda Jones Retirement VillageHamilton34132214.0%1.4%1.9%2.4%3.0%3.5%

Patrick Hogan Retirement VillageCambridge909316.0%1.5%2.0%2.5%3.0%3.5%

Bob Owens Retirement VillageTauranga29728413.5%1.4%1.9%2.4%3.0%3.5%

Kiri Te Kanawa Retirement VillageGisborne1669615.5%1.3%1.7%1.9%2.2%3.0%

Princess Alexandra Retirement VillageNapier1269714.0%1.3%1.8%2.3%2.7%3.4%

James Wattie Retirement VillageHavelock North22520414.5%1.1%1.7%2.4%2.8%3.5%

Jane Winstone Retirement VillageWhanganui1046016.0%1.3%1.7%1.9%2.2%2.5%

Julia Wallace Retirement VillagePalmerston North16113214.3%1.3%1.8%2.3%2.7%3.3%

Jean Sandel Retirement VillageNew Plymouth23117114.0%1.4%1.9%2.4%2.7%3.3%

Charles Fleming Retirement VillageWaikanae28025313.5%1.4%1.9%2.5%3.0%3.5%

Shona McFarlane Retirement VillageWellington18015314.0%1.4%1.9%2.4%2.9%3.5%

Bob Scott Retirement VillageWellington34333613.5%1.4%1.9%2.4%2.9%3.5%

Malvina Major Retirement VillageWellington16215814.0%1.4%1.9%2.4%2.9%3.5%

Rita Angus Retirement VillageWellington14813713.5%1.4%1.9%2.4%2.9%3.5%

Ernest Rutherford Retirement VillageNelson19914813.5%1.3%1.8%2.3%3.0%3.5%

Charles Upham Retirement VillageRangiora35125713.5%1.4%1.9%2.4%3.0%3.5%

Anthony Wilding Retirement VillageChristchurch16012613.5%1.3%1.8%2.3%3.0%3.5%

Kevin Hickman Retirement VillageChristchurch22018714.5%1.4%1.9%2.4%3.0%3.5%

Diana Isaac Retirement VillageChristchurch33526513.3%1.4%1.9%2.4%3.0%3.5%

Ryman Northwood Retirement VillageChristchurch12211415.8%1.5%2.0%2.5%3.0%3.5%

Essie Summers Retirement VillageChristchurch804814.3%1.1%1.6%2.1%2.6%3.3%

Margaret Stoddart Retirement VillageChristchurch412216.0%1.3%1.8%2.3%2.7%3.3%

Ngaio Marsh Retirement VillageChristchurch15911913.8%1.4%1.9%2.4%3.0%3.5%

Woodcote Retirement VillageChristchurch251216.5%1.4%1.9%2.4%2.7%3.0%

Frances Hodgkins Retirement VillageDunedin744814.8%1.3%1.6%1.9%2.1%3.0%

Yvette Williams Retirement VillageDunedin322214.5%1.0%1.5%1.8%2.0%3.0%

Rowena Jackson Retirement VillageInvercargill1497915.5%1.4%1.7%1.9%2.2%2.9%

Eastmed Medical CentreAuckland17

Subtotal of fair value villages (NZD)8,3858,25014.0%1.4%1.9%2.4%2.9%3.4%

RYMAN HEALTHCARE | 1H26 Results Presentation56
Appendix 7: Investment property valuation – key assumptions

Appendices

Australia villages

VillageLocationUnitsValuation ($m)Discount rateGrowth rate Yr 1Growth rate Yr 2Growth rate Yr 3Growth rate Yr 4Growth rate Yr 5+

Charles Brownlow Retirement VillageMelbourne14013513.0%2.3%2.3%2.3%2.3%2.8%

John Flynn Retirement VillageMelbourne26936313.0%1.9%1.9%1.9%1.9%2.5%

Nellie Melba Retirement VillageMelbourne41757713.0%1.9%1.9%1.9%1.9%2.5%

Weary Dunlop Retirement VillageMelbourne24829913.0%2.1%2.1%2.1%2.1%2.5%

Raelene Boyle Retirement VillageMelbourne9114313.3%2.1%2.1%2.1%2.1%2.6%

Deborah Cheetham Retirement VillageMelbourne19123113.5%1.0%2.0%2.0%2.0%2.6%

Bert Newton Retirement VillageMelbourne13019414.0%0.8%1.6%2.1%2.1%2.4%

Hubert Opperman Retirement VillageMelbourne5110014.0%1.0%2.0%2.0%2.0%3.3%

Essendon Terrace Retirement VillageMelbourne363113.8%2.0%2.0%2.0%2.0%3.3%

Subtotal of fair-value villages (NZD)1,5732,07513.2%1.7%2.0%2.0%2.0%2.6%

Total portfolio

VillageLocationUnitsValuation ($m)Discount rateGrowth rate Yr 1Growth rate Yr 2Growth rate Yr 3Growth rate Yr 4Growth rate Yr 5+

Australia1,5732,07513.2%1.7%2.0%2.0%2.0%2.6%

New Zealand8,3858,25014.0%1.4%1.9%2.4%2.9%3.4%

Total (NZD)9,95810,32513.8%1.4%1.9%2.3%2.7%3.3%

RYMAN HEALTHCARE | 1H26 Results Presentation57
Appendix 8: Balance sheet summary

$m

Mar-25

(reported)Restatements

Mar-25

(restated)

1H26

movementsSep-25

Cash and cash equivalents18-18(9)9

Trade and other receivables164-164(14)150

Assets held for sale33-33033

Property, plant & equipment1,020-1,020101,030

Investment properties10,813(77)10,73617810,914

Intangible assets14-14(2)12

Other assets

1

3-3(1)2

Total assets12,063(77)11,98616312,150

Trade and other payables114-114(12)101

Interest bearing loans and borrowings1,683-1,683(23)1,660

Resident loans - occupancy advances5,217-5,2171605,378

Resident loans - RADs497-49743539

Other liabilities

2

292-29244337

Total liabilities7,802-7,8022128,014

Total equity4,261(77)4,184(49)4,135

-

Net tangible assets (NTA)

3

4,247(77)4,170(47)4,123

Shares on issue (m)1,016-1,01601,016

per share (cps)418.2(7.6)410.6(4.6)406.0

Net interest-bearing debt

4

1,665-1,665(14.1)1,650.8

Gearing

5

28.1%0.4%28.5%0.1%28.5%

1: Includes inventory, advances to employees, and derivative financial instruments. 2: Includes employee entitlements, revenue in advance, derivative financial instruments, lease liabilities and deferred tax liability.

3: Total equity less intangible assets. 4: Interest bearing loans and borrowings less cash and cash equivalents. 5: Net interest-bearing debt to net interest-bearing debt plus total equity.

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation58
Appendix 9: Key funding metrics

Interest bearing debt ($000s)Financial statement referenceSep-24Mar-25Sep-25

Sep-25

pro-forma

4

NZD bank loans1,476,980527,200506,850506,850

AUD bank loans691,8891,009,2361,005,8071,005,807

AUD institutional term loan272,183---

NZD retail bond150,000150,000150,000150,000

Drawn interest bearing debt at face value2,591,0521,686,4361,662,6571,662,657

IFRS adjustments(11,405)(3,884)(2,968)(2,968)

Interest bearing loans and borrowings per balance sheetBalance sheet2,579,6471,682,5521,659,6891,659,689

Cash and cash equivalentsBalance sheet(22,573)(17,658)(8,913)(8,913)

Net interest-bearing debt2,557,0741,664,8941,650,7761,650,776

Facilities and headroom ($000s)Financial statement referenceSep-24Mar-25Sep-25

Sep-25

pro-forma

4

Total facilities at face value3,023,5332,209,2742,239,3372,197,776

Drawn interest bearing debt at face value2,591,0521,686,4361,662,6571,662,657

Debt headroom432,481522,838576,680535,119

Cash and cash equivalentsBalance sheet22,47517,6588,9138,913

Total funding headroom454,956540,496585,593544,032

Weighted average term to expiry of all debt facilities2.7 years2.7 years2.2 years4.8 years

Interest rate management ($000s)Sep-24Mar-25Sep-25

Sep-25

pro-forma

4

Total active fixed rate debt

1

1,651,0211,137,6671,126,5571,126,557

Weighted average term of fixed rate debt3.3 years1.7 years1.2 years 1.2 years

Percentage of drawn debt at face value at fixed rates64%67%68%68%

Weighted average interest rate on drawn fixed rate debt

2

5.9%6.0%6.0%5.7%

Weighted average interest rate on all drawn debt

3

6.5%6.1%6.0%5.7%

1: Includes retail bond and interest rate swaps. 2: Total cost of fixed rate debt including retail bond (fixed coupon), fixed portion of institutional term loan (fixed coupon) and interest rate swaps (fixed swap rate plus average

margin and line fees on bank debt, including margin on undrawn facilities weighted on drawn facilities). Excludes amortisation of establishment fees. 3: Total cost of all debt including fixed rate debt, floating rate debt and line

fees on bank debt, including margin on undrawn facilities weighted on drawn facilities. Excludes derivative termination costs relating to ITL and amortisation of establishment fees. 4: Pro-forma at 30 September including impact

from refinancing which occurred on 24 November 2025.

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation59
Appendix 10: Finance costs

1: Gross interest paid in 1H26 benefited from a change in payment terms for line fees of approximately $5.6 million. 2: Expensed through profit and loss in FY25. Refer note 6 in the FY25 Consolidated Financial Statements.

Appendices

Finance costs ($m)

1H25

(restated)1H26YoY $

Profit and loss

Interest expense on loans and borrowings(92.9)(49.6)43.2

Amortisation of issue costs on loans and borrowings(2.3)(0.9)1.3

Release of cash-flow hedge reserve14.7(1.0)(15.6)

Gross interest costs on borrowings(80.4)(51.5)28.9

Borrowing costs capitalised to sites under construction25.28.8(16.5)

Borrowing costs capitalised to land bank sites6.4-(6.4)

Total borrowing costs capitalised31.68.8(22.8)

Net interest costs on borrowings(48.8)(42.7)6.1

Interest on lease liabilities(0.0)(0.1)(0.1)

Interest rate swaps and collars amendments (non-cash)(4.3)3.98.2

Total finance costs(53.2)(39.0)14.2

Cash flow

Interest paid within (operating activities)(48.9)(36.6)12.3

Capitalised interest paid (investing activities)(31.6)(8.8)22.8

Gross interest paid

1

(80.5)(45.4)35.1

Derivative termination costs relating to ITL

2

-(4.8)(4.8)

Total cash finance costs(80.5)(50.2)30.3

RYMAN HEALTHCARE | 1H26 Results Presentation60
5.7%

5.7%

5.6%

6.1%

6.1%

6.2%

6.3%

6.3%

6.4%

6.2%

6.0%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

Sept 25Mar 26Sept 26Mar 27Sept 27Mar 28Sept 28Mar 29Sept 29Mar 30Sept 30

150 150 150

- - -

435

485 485

480

410

250 250

190 190

35

-

542

542 542

507

507

473

416

382

239

239

57

1,127

1,177 1,177

987

917

723

666

572

429

274

57

-

200

400

600

800

1,000

1,200

1,400

Sept 25Mar 26Sept 26Mar 27Sept 27Mar 28Sept 28Mar 29Sept 29Mar 30Sept 30

Retail bondNZD swaps and collarsAUD swaps and collars

Total fixed rate debt

Average interest rate on fixed rate debt

2

(%)

(pro-forma)

3

Appendix 11: Fixed rate debt profile

1: All amounts shown in NZD. AUD fixed rate debt instruments converted to NZD at 30 September 2025 NZD/AUD rate of 0.8771. 2: Total cost of fixed rate debt including retail bond (fixed coupon) and interest rate swaps (fixed swap rate

plus average margin and line fees on bank debt, including margin on undrawn facilities weighted on drawn facilities). 3: Pro-forma at 30 September including impact from refinancing which occurred on 24 November 2025.

Appendices

Notional value of fixed debt ($m)

1

RYMAN HEALTHCARE | 1H26 Results Presentation61
Appendix 12: Gross resale bank and resales affordability

1: Gross resale bank reflects the cumulative difference between current pricing ORA for RV units and ORA repayment amount (previous ORA price for occupied units and unoccupied units yet to be repaid, and nil for paid out units). This

excludes resident incentives, selling costs, suspended contributions and unit refurbishment costs. September 2024 onwards is calculated on an occupation basis, while prior periods are on a contracted basis. 2: The average price shown

for Ryman units is for resales only. The median house price reflects the average median house price over the last 6 months in the areas surrounding our villages.

Gross resale bank ($m)

1

Resales affordability ($m)

2

2

Appendices

1.61

1.15

0.73

0.93

1.01

0.72

0.74

0.65

0.51

-

$0.3m

$0.6m

$0.9m

$1.2m

$1.5m

$1.8m

Melbourne (A$)Auckland (NZ$)Rest of NZ (NZ$)

Median house price - village areasRyman - 2 bed independentRyman - serviced

1.77

1.60

1.55

1.43

1.45

1.38

1.36

0.18

0.18

0.16

0.18

0.18

0.16

0.16

1.95

1.78

1.71

1.61

1.63

1.54

1.52

-

$0.50b

$1.00b

$1.50b

$2.00b

$2.50b

Sep-22Mar-23Sep-23Mar-24Sep-24Mar-25Sep-25

New ZealandAustraliaTotal

RYMAN HEALTHCARE | 1H26 Results Presentation62
Appendix 13: Aged care summary

New Zealand aged care centresAustralia aged care centres

1: Care centres are considered mature when they first reach 90% occupancy for a full financial year and exclude villages with operational impacts. Mature care centres in New Zealand declined by two due to the exclusion of

Woodcote and Margaret Stoddart which commenced closure in the period. Mature care centres in Australia increased by one due to the inclusion of John Flynn. 2: In New Zealand, the implicit interest rate to convert a room

premium to a refundable accommodation deposit is used to calculate the imputed income (1H26: 6.06%, 1H25: 6.06%). In Australia the maximum permissible interest rate (MPIR) is used to calculate imputed interest (1H26: 7.78%–8.17%,

1H25 8.34%–8.36%). Imputed income on RADs is not calculated on RAD balances subject to probate in Australia. 3: Where residents have opted for a room premium / RAD combination in New Zealand, or DAP / RAD combination in

Australia, penetration and no. outstanding RADs are presented on a proportional basis.

Appendices

Unit1H251H26YoY

Operational care centres#37383%

Mature care centres

1

#3331(6%)

Operational care beds#3,9414,0222%

Mature care beds#3,4663,372(3%)

Proportion of care beds - mature%88%84%

Occupancy

Occupied bed days#647,484673,0314%

Capacity bed days#695,258727,5065%

Occupancy%93.1%92.5%-0.6 pp

Occupancy - mature%96.2%96.1%-0.1 pp

Revenue

Care fees - base fees$m159.0173.09%

Care fees - room premiums$m25.129.417%

Imputed income on RADs

2

$m4.75.06%

Deferred management fees (DMF)$m0.10.2172%

Total aged care revenue$m188.9207.610%

Revenue per occupied bed per week$2,0422,1596%

Penetration - premium and RAD rooms

3

Beds with room premium%73%75%2 pp

Beds with RAD%9%10%0 pp

Beds with room premium or RAD%82%84%2 pp

RAD balance

Total RAD balance$m163.5165.91%

No. outstanding RADs

3

#3413523%

Average RAD balance$480,000472,000(2%)

Note all figures in NZD equivalent

Unit1H251H26YoY

Operational care centres#6717%

Mature care centres

1

#4525%

Operational care beds#68075912%

Mature care beds#44656026%

Proportion of care beds - mature%66%74%

Occupancy

Occupied bed days#103,469115,95212%

Capacity bed days#124,440138,89712%

Occupancy%83.1%83.5%0.3 pp

Occupancy - mature

%

97.7%96.1%-1.7 pp

Revenue

Care fees - AN-ACC, basic daily fee, other$m39.048.825%

Care fees - DAP$m2.93.418%

Imputed income on RADs

2

$m11.012.110%

Total aged care revenue$m52.964.322%

Revenue per occupied bed per week

$

3,5803,8838%

Penetration - non-concessional rooms

3

Beds with DAP%20%18%-2 pp

Beds with RAD%63%60%-3 pp

Beds with RAD or DAP

%

83%78%-5 pp

RAD balance

Total RAD balance$m305.6373.222%

Probate balance$m(35.3)(50.7)44%

Total RAD balance (exc. probate)$m270.3322.519%

No. outstanding RADs

3

#3653948%

Average RAD balance$741,000818,00010%

Average RAD balance AUD

$

681,000718,0005%

RYMAN HEALTHCARE | 1H26 Results Presentation63
Appendix 14: Revenue by operating segment

1: Serviced apartment DMF presented excludes -$12.0 million historical adjustments relating to GST and uncapped internal transfers related to prior periods

Appendices

Aged care beds ($m)Unit1H251H26YoY

Care fees$m226.0254.613%

Imputed income on RADs$m15.717.19%

DMF$m0.10.2173%

Total aged care revenue$m241.8271.912%

Occupied bed days#750,953788,9835%

Revenue per bed per week$2,2542,4137%

Serviced apartments ($m)1H251H26YoY

Village fees$m28.130.17%

DMF

1

$m22.218.4-17%

Total serviced apartment revenue$m50.348.5-3%

Occupied unit days #394,138394,6070%

Village fees per unit per week$5005347%

Revenue per unit per week$893861-4%

Independent units ($m)1H251H26YoY

Village fees$m22.926.114%

DMF$m55.559.47%

Total independent unit revenue$m78.485.59%

Occupied unit days#1,126,8271,175,3844%

Village fees per unit per week $14215610%

Revenue per unit per week$4875095%

RYMAN HEALTHCARE | 1H26 Results Presentation64
Appendix 15: Free cash flow

1

Appendices

$m

1H25

(restated)1H26YoY

Alternative cash flow presentation

Cash flow from existing operations (CFEO

1

)(24.4)(23.1)1.3

Cash flow from development activity (CFDA

1

)(28.1)79.3107.4

Free cash flow(52.5)56.2108.7

Reconciliation to IFRS cash flow statement

Net operating cash flows261.1172.9(88.2)

Net investing cash flows(315.2)(120.7)194.6

Derivative termination costs related to ITL

2

-4.84.8

Repayment of lease liabilities

3

(2.1)(1.3)0.8

Purchase of treasury stock (net)

3

3.80.5(3.3)

Free cash flow

1

(52.5)56.2108.7

1: The metric is classified as non-GAAP, meaning it does not adhere to a standardised definition under GAAP (Generally Accepted Accounting Practice). Non-GAAP measures are presented to assist investors in understanding

Ryman's performance. It may not be comparable to similar financial information presented by other entities. 2: ITL cash break costs of $23.9 million (2H25: $19.0 million, 1H26: $4.8 million) incurred for prepayment of ITL and

related derivative termination costs excluded for consistency with free cash flow guidance provided at the time of the February 2025 equity raise. 3: Included in net financing cash flows on IFRS cash flow statement. Included in

cash flow from existing operations (CFEO) in alternative cash flow presentation.

RYMAN HEALTHCARE | 1H26 Results Presentation65
Appendix 16: Alternative cash flow detail

Appendices

Resident funding from RV units ($m)Financial statement reference

1H25

(restated)1H26YoY

New sales of occupation rights

Gross new sale settlements

206.1170.9(35.2)

Suspended contributions on new sales

(2.4)(2.9)(0.5)

Settlements on new sales

203.8168.0(35.7)

Resales of occupation rights

Gross resale settlements

431.6383.7(47.9)

Suspended contributions on resales

(23.6)(21.7)1.9

Settlements on resales

407.9362.0(46.0)

Total sales of occupation rights

Gross settlements on total sales

637.7554.6(83.1)

Suspended contributions on total sales

(26.0)(24.6)1.4

Settlements on total salesCash flow statement

611.7530.0(81.7)

Repayment of occupation rights

Gross resale repayments

(285.1)(303.3)(18.1)

Suspended contributions on repayments

12.315.73.4

Repayment of occupation rightsCash flow statement

(272.8)(287.6)(14.7)

Suspended contributions

Suspended contributons balance - opening balanceNote 13

(98.2)(119.4)(21.2)

Suspended contributons balance - closing balanceNote 13

(111.9)(128.2)(16.4)

Movement in suspended contributions

(13.7)(8.9)4.8

RYMAN HEALTHCARE | 1H26 Results Presentation66
Appendix 16: Alternative cash flow detail cont.

Appendices

Payments to suppliers and employees ($m)Financial statement reference

1H25

(restated)1H26YoY

Included in cash flow from existing operations

Village operations(282.4)(307.9)(25.6)

Non-village cash flow(60.2)(50.6)9.5

Sales and marketing expenses - resales

Direct selling expenses(4.7)(1.7)3.0

Employee expenses(2.9)(2.7)0.2

Marketing(6.1)(6.5)(0.4)

Subtotal CFEO(356.2)(369.5)(13.2)

Included in cash flow from development activity

Land bank expenses-(3.2)(3.2)

Sales and marketing expenses - new sales

Direct selling expenses(2.4)(0.4)2.0

Employee expenses(1.9)(1.4)0.4

Marketing(5.1)(3.9)1.2

Subtotal CFDA(9.4)(8.9)0.5

Total payments to suppliers and employeesCash flow(365.6)(378.4)(12.8)

RYMAN HEALTHCARE | 1H26 Results Presentation67
Appendix 16: Alternative cash flow detail cont.

Appendices

Cash management fees ($m)Financial statement reference

1H25

(restated)1H26YoY

Accrued DMF - openingNote 13

(713.8)(830.4)(116.7)

Accrued DMF - closingNote 13

(766.2)(903.8)(137.6)

Movement in accrued DMF

(52.4)(73.3)(20.9)

Revenue in advance - openingBalance sheet

140.9184.043.2

Revenue in advance - closingBalance sheet

160.8216.956.1

Movement in revenue in advance

20.032.912.9

Plus: DMF revenue

65.878.012.2

Plus: Historical GST adjustment

8.3-(8.3)

Plus: Accommodation credit adjustment / FX movement

(0.2)5.35.4

Cash management fees

1

41.442.91.5

Capex ($m)

1H25

(restated)1H26YoY

Property capex

17.413.3(4.0)

Technology capex

3.42.3(1.1)

Capex on existing villages and technology

20.815.7(5.1)

RV unit refurbishments

16.413.6(2.8)

Head office and other projects

4.91.3(3.6)

Capex on existing operations

42.130.6(11.6)

Land acquisitions

18.32.0(16.3)

Direct construction capex

220.176.2(143.9)

Capitalised interest

31.68.8(22.8)

Non-village expenses capitalised to projects

11.14.5(6.5)

Capex on development activity

281.191.6(189.5)

Total capex

323.2122.1(201.1)

1: Included within cash flow from exiting operations

RYMAN HEALTHCARE | 1H26 Results Presentation68
Appendix 17: Glossary

TermDefinition

AUAustralia.

Capex

(non-GAAP)

Capital expenditure (capex) refers to capital expenditure to acquire, upgrade,

maintain property, plant and equipment, investment property and intangible assets.

Care bedRest home, hospital and dementia level care.

Care capitalAdvances received from residents for rest home, hospital and dementia level care

rooms or care suites including RADs or ORAs (with the latter having a DMF charge).

Cash flow from

development activity

(non-GAAP)

Cash flow from development activity (CFDA) includes resident receipts from new sales

of occupation rights, the net increase in refundable accommodation deposits on aged

care beds, net development capex, land bank expenses, notional interest on new stock

and land bank, and marketing expenses allocated to new sales.

Cash flow from existing

operations

(non-GAAP)

Cash flow from existing operations (CFEO) includes operating villages, shared services

functions and expensed interest (adjusted for notional interest attributed to CFDA),

demonstrating net cash flow to equity holders on existing business operations, excluding

cash flows relating to development of new villages.

Continuum of careCo-location of independent living units, serviced apartments and aged care beds

within the same village, alongside a broad range of aged-related healthcare and

support services, including home care in some villages.

DMFDeferred management fee.

Operating EBITDAF

(non-GAAP)

Earnings before interest, tax, depreciation, amortisation and fair value movements,

excluding non-operating items.

Free cash flow

(non-GAAP)

Free cash flow combines cash flow from existing operations (CFEO)

and cash flow from development activity (CFDA), reflecting all operating and

development cash flows.

FYFinancial year ended 31 March.

Gearing

(non-GAAP)

Net interest-bearing debt / (Net interest-bearing debt + equity), pre IFRS-16.

GreenfieldPreviously undeveloped sites.

Gross Resale MarginThe difference between the previous purchase price of an ORA and its new purchase

price divided by the new purchase price. Excludes resident incentives, selling costs,

suspended contributions and unit refurbishment costs.

ICRInterest coverage ratio.

ILUIndependent living unit.

ITLInstitutional term loan.

TermDefinition

Main buildingMain buildings contain care beds, serviced apartments and a range of village

amenities such as a café, library, cinema, pool, gym etc. Some main buildings also

contain independent apartments.

Net interest-bearing

debt

Interest-bearing debt loans and borrowings less cash and cash equivalents. Excludes

lease liabilities

Non-GAAPThis is a non-GAAP measure which does not have a standardised meaning prescribed

by GAAP (Generally Accepted Accounting Practice). This non-GAAP measure has

been presented to assist investors in understanding Ryman's performance. It may not be

comparable to similar financial information presented by other entities.

NTANet tangible assets. Calculated as total assets less intangible assets and deferred tax

assets, and less total liabilities.

NZNew Zealand.

ORAAn occupation right agreement within the meaning of the Retirement Villages Act 2003

(for Villages in New Zealand) or a residence and management contract within the

meaning of the Retirement Villages Act 1986 (Vic) (for Villages in Australia).

Payout balanceGross amounts (inclusive of DMF) paid out on existing RV units for vacating residents or

internal transfers where the unit has not been settled under a new ORA.

Pro-formaAdjusted for the impact of the bank refinancing.

RADRefundable accommodation deposit.

ResalesThe sale of an ORA on an existing unit when a resident departs a unit.

ResidentA person who is resident in a Ryman Village in an ILU, SA or care bed.

Resident fundProduct tailored for Ryman residents moving from ILU or SA to aged care that enables

the transfer of some or all equity to reduce room premium. Only available in New

Zealand.

RVRetirement village. A retirement village unit includes ILUs and SAs, excludes

care beds.

SAServiced apartment.

Total capexNet investing cash flows per the consolidated statement of cash flows. This includes

purchases of investment properties, property, plant and equipment, land, intangible

assets, capitalised interest paid, excluding proceeds from land or asset sales.

UnitAny independent unit or serviced apartment that can be occupied.

VillageAny retirement village owned by Ryman (or its subsidiaries) that:

• in New Zealand is registered as a retirement village under the

Retirement Villages Act 2003; and

• in Australia is registered as a retirement village under The Retirement

Villages Act 1986 (Vic).

Appendices

RYMAN HEALTHCARE | 1H26 Results Presentation69
Disclaimer

This presentation has been prepared by Ryman

Healthcare Limited and its group companies

(‘Ryman’) for informational purposes.This

disclaimer applies to this document and the verbal

or written comments of any person presenting it.

This presentation provides additional comments on

the half year result for the period to 30 September

2025 presented on 27 November 2025. It should be

read in conjunction with all other material which

we have released, or may release, to NZX from

time to time. That material is also available on our

website at rymanhealthcare.com

.

Purpose of this presentation

This presentation isnot an offer of financial products, or a proposal or invitation to make

any such offer.It is not investment advice, or any otheradvice, or a recommendation in

relation to financial products, and does not take into account any person’s individual

circumstances or objectives. Every investor should make an independent assessment of

Ryman on the basis of expert financial advice.

Forward-looking statements

This presentation contains forward-looking statements and projections.These reflect our

current expectations, based on what we think are reasonable assumptions.However, any

of these forward-looking statements or projections may be materially different due to a

range of factors and risks. Ryman gives no warranty or representation as to our future

financial performance or any future matter.Actual results may differ materially from those

projected.Except as required by law or the NZX Listing Rules, Ryman undertakes no

obligation to update any forward-looking statements whether as a result of new

information, future events, or otherwise.

Non-GAAP information

A number offinancial measures used in this presentation are based on non-Generally

Accepted Accounting Practice (GAAP) measures which do not have a standardised

meaning prescribed by GAAP. You should not considerany of these financial measures in

isolation, or in substitution for the information provided in the financial statements for the

six months ended 30 September 2025.

Appendices

---

p

30 September 2025

RYMAN HEALTHCARE


Consolidated

interim financial

statements











RYMAN HEALTHCARE LIMITED
Consolidated income statement

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

The accompanying notes form part of these consolidated interim financial statements.


1


Sep 2024

Note Sep 2025

(restated)

$000 $000


Care and village fees 310,850 277,016

Deferred management fees (DMF) 78,042 65,798

Interest received 312 1,112

Imputed income on refundable accommodation

deposits


17,080 15,715

Other income 7,496 6,622

Total revenue 413,780 366,263


Operating expenses 3

(376,927) (373,405)

Depreciation and amortisation expenses

(21,811) (24,940)

Finance costs (38,967) (53,204)

Imputed interest charge on refundable accommodation

deposits


(17,080) (15,715)

Impairment loss 6 (2,436) -

Total expenses (457,221) (467,264)


Profit/(loss) before income tax and

fair value movements (PBTF)


(43,441) (101,001)


Fair value movement of investment properties 7 3,248 270,057

Profit/(loss) before income tax (40,193) 169,056

Income tax (expense)/credit 4 (5,001) (87,054)

Net profit/(loss) after tax (NPAT) (45,194) 82,002


Earnings per share (cents per share)

Basic 8 (4.4) 11.9

Diluted 8 (4.4) 11.8


Profit/(loss) before income tax and fair value movements (PBTF) is a non-GAAP measure which does not have

a standardised meaning prescribed by GAAP (Generally Accepted Accounting Practice). This non-GAAP

measure has been presented to assist investors in understanding the Group’s performance. It may not be

comparable to similar financial information presented by other entities.




RYMAN HEALTHCARE LIMITED
Consolidated statement of comprehensive income

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

The accompanying notes form part of these consolidated interim financial statements.


2

Sep 2024

Note Sep 2025

(restated)

$000 $000


Net profit/(loss) after tax (45,194) 82,002


Items that will not be later reclassified to profit or loss

Revaluation of property, plant and equipment, net of tax 4,6

(802) -

(802) -


Items that may be later reclassified to profit or loss


Fair value movement and reclassification of cash-flow

hedge reserve, net of tax



(10,915) (22,746)

Gain/(loss) on hedge of foreign-owned subsidiary net

assets


(2,784) 175

Gain/(loss) on translation of foreign operations 10,050 (440)

(3,649) (23,011)


Other comprehensive income/(loss) (4,451) (23,011)

Total comprehensive income/(loss) (49,645) 58,991









RYMAN HEALTHCARE LIMITED Consolidated statement of changes in equity

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


The accompanying notes form part of these

consolidated interim fi

nancial statements.


3


Issued

capital


Asset

revaluation

reserve


Cash flow

hedge

reserve


Foreign

translation

reserve


Treasury

stock


Share-based

payments

reserve

Retained

earnings


Total equity



$000


$000


$000


$000


$000


$000 $000


$000




As at 1 April 2024

952,887

126,290

20,774

3,551

(34,730)

-

2,677,601

3,746,373

Net profit/(loss) after tax

-

-

-

-

-

-

82,002

82,002

Other comprehensive income/(loss)

- - (22,746) (265) - - - (23,011)

Total comprehensiv

e income/(loss)

- - (22,746) (265) - - 82,002 58,991

Sale of treasury stock and loss on

sale - - - - 11,735 - (8,389) 3,346

Equity-settled share-base

d payment - - - - - 127 - 127

As at 30 September 2024 – restated

952,887

126,290

(1,972)

3,286

(22,995)

127

2,751,214

3,808,837



As at 1 April 2025 – reported


1,923,044

116,649

1,704

6,979

(16,280)

348

2,228,679

4,261,123

Adjustment for prior period

1


-

-

-

-

-

-

(76,916)

(76,916)

As at 1 April 2025 – restated

1,923,044

116,649

1,704

6,979

(16,280)

348

2,151,763

4,184,207

Net profit/(loss) after tax

-

-

-

-

-

-

(45,194)

(45,194)

Other comprehensive income/(loss)

-

(802)

(10,915)

7,266

-

-

-

(4,451)

Total comprehensiv

e income/(loss)

-

(802)

(10,915)

7,266

-

-

(45,194)

(49,645)

Issue of ordinary shares

58

-

-

-

-

(58)

-

-

Sale of treasury stock and loss on sale

-

-

-

-

2,485

-

(2,032)

453

Equity-settled share-based payment

-

-

-

-

-

374

-

374

As at 30 September 2025

1,923,102

115,847

(9,211)

14,245

(13,795)

664

2,104,537

4,135,389



1

Investment property and related fair value gains as at 31 Marc

h 2025 have been restated. Please refer to Note 1 for further de

tails.

RYMAN HEALTHCARE LIMITED
Consolidated statement of financial position

AS AT 30 SEPTEMBER 2025


4



Authorised for issue on 26 November 2025 on behalf of the Board.






Dean Hamilton James Miller

Director & Chair of the Board Director & Chair of the Audit, Finance and Risk Committee


Note Sep 2025

Mar 2025

(restated)


$000 $000

Assets

Cash and cash equivalents 8,913 17,658

Trade and other receivables 9 149,501 163,921

Inventory 13 13

Advances to employees 1,464 1,505

Derivative financial instruments 12 452 1,385

Property, plant and equipment 6 1,029,987 1,019,595

Investment properties 7 10,913,952 10,735,626

Intangible assets 12,024 13,817

Deferred tax assets 4 - -

12,116,306 11,953,520

Assets held for sale 5 33,285 32,926

Total assets 12,149,591 11,986,446


Equity

Issued capital 8

1,923,102 1,923,044

Reserves 107,750 109,400

Retained earnings 2,104,537 2,151,763

Total equity 4,135,389 4,184,207


Liabilities


Trade and other payables 10

101,128 113,578

Employee entitlements 82,874 80,240

Revenue in advance 216,931 184,020

Refundable accommodation deposits 539,144 496,639

Derivative financial instruments 12 25,296 15,340

Interest-bearing loans and borrowings 11 1,659,689 1,682,552

Occupancy advances 13 5,377,620 5,217,158

Lease liabilities 11,520 12,712

Total liabilities 8,014,202 7,802,239


Total equity and liabilities

12,149,591 11,986,446

RYMAN HEALTHCARE LIMITED
Consolidated statement of cash flows

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


5


Sep 2024

Sep 2025 (restated)

$000 $000

Operating activities

Receipts from residents

 Care and village fees 317,046 284,131

 Net refundable accommodation deposits 32,889 51,445

 New sale and resales of occupation rights 529,983 611,686

Interest received 344 1,163

Payments to suppliers and employees (378,352) (365,591)

Repayment of occupational rights (287,566) (272,834)

Interest paid (36,626) (48,908)

Derivative termination costs related to Institutional Term Loan (4,819) -

Net operating cash flows 172,899 261,092


Investing activities


Development of property, plant and equipment (16,344) (72,481)

Purchase of land (2,000) (18,304)

Proceeds from land sales - 7,128

Purchase of intangible assets (292) (1,965)

Development of investment properties (94,714) (198,848)

Proceeds from sale of property, plant and equipment 1,400 -

Capitalised interest paid (8,776) (31,598)

Receipt of employee loans 41 828

Net investing cash flows (120,685) (315,240)


Financing activities


Drawdown/(Repayment) of bank loans (net) (60,146) 33,246

Sale of treasury stock (net) 453 3,763

Repayment of lease liabilities (1,266) (2,097)

Net financing cash flows (60,959) 34,912


Net (decrease)/increase in cash and cash equivalents

(8,745) (19,236)

Cash and cash equivalents at the beginning of the period 17,658 41,809

Cash and cash equivalents at the end of the period 8,913 22,573

Net operating cash flows includes the following:

Sep 2025 Sep 2024

$000 $000

Deferred management fees collected 42,909 41,434

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


6


The notes to the consolidated interim financial statements include information that is considered relevant and

material to assist the reader in understanding changes in the Group’s financial position and performance.

Information is considered relevant and material if:

 The amount is material because of its size or nature

 It is important for understanding the results of the Group

 It helps explain changes in the Group’s business

 It relates to an aspect of the Group’s operations that is important to future performance.

1. GENERAL INFORMATION

The consolidated interim financial statements presented are those of Ryman Healthcare Limited (the

Company) and its subsidiaries (the Group). These consolidated interim financial statements were approved by

the Board of Directors on 26 November 2025.

The Company is a profit-oriented entity incorporated and registered in New Zealand under the Companies

Act 1993. The Company’s registered office is at 92d Russley Road, Christchurch. The Company is listed on the

New Zealand Stock Exchange (NZX), being the Company’s primary exchange, and is listed on the Australian

Securities Exchange (ASX) as a foreign exempt listing. The Group develops, owns and operates integrated

retirement villages, rest homes and hospitals for older people within New Zealand and Australia.

All trading subsidiaries operate in the aged care and retirement village sector in New Zealand and Australia,

are 100% owned and have a balance date of 31 March. A list of subsidiaries can be found in the 2025 Annual

Report.

Statement of compliance

The Company is a Financial Markets Conduct reporting entity under the Financial Reporting Act 2013 and the

Financial Markets Conduct Act 2013. Its consolidated interim financial statements comply with these Acts.


The consolidated interim financial statements have been prepared in accordance with Generally Accepted

Accounting Principles in New Zealand (NZ GAAP). The statements comply with New Zealand equivalents to

International Accounting Standard 34 Interim Financial Reporting (NZ IAS 34) and International Accounting

Standard 34 Interim Financial Reporting (IAS 34).

Basis of preparation


These consolidated interim financial statements have been prepared on a going concern basis, which

requires the Board to have reasonable grounds to believe that the Group will be able to pay their debts as

and when they become due.

The information is presented in thousands of New Zealand Dollars ($ or NZD), except when otherwise indicated.

The functional currency of the Company and its New Zealand subsidiaries is New Zealand Dollars. The

functional currency for its Australian subsidiaries is Australian Dollars (A$ or AUD).

The consolidated interim financial statements for the six months ended 30 September 2025 and 30 September

2024 are unaudited, with the six months ended 30 September 2025 period reviewed by the independent

auditor, pursuant to NZ SRE 2410 (Revised) Review of Financial Statements Performed by the Independent

Auditor of the Entity, issued by the External Reporting Board.

These consolidated interim financial statements do not include all the notes included in the Group’s financial

statements. Accordingly, these consolidated interim financial statements should be read in conjunction with

the financial statements and related notes included in the Annual Report for the year ended 31 March 2025.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


7


In applying the Group’s accounting policies, the Board makes judgements, estimates and assumptions that

may have an impact on the Group. The significant judgements, estimates and assumptions made in the

preparation of these consolidated interim financial statements were the same as those applied to the

consolidated financial statements as at and for the year ended 31 March 2025, except as otherwise stated.

Changes in financial reporting

Accounting policies are selected and applied in a way that seeks to ensure the resulting financial information

satisfies the concepts of relevance and reliability, and the substance of the underlying transactions or other

events is reported.

The Group disclosed at 31 March 2025 that it had completed an extensive review of its financial reporting with

the goal of enhancing the transparency of its results and ensuring greater comparability with others in the

sector. Where applicable, these changes were applied to the annual reporting periods of 31 March 2025 and

31 March 2024. The changes made at 31 March 2025 have been retrospectively applied to the 30 September

2024 comparative period in the consolidated interim financial statements. These changes have been

summarised below, with the impact of these on the 30 September 2024 comparative period reported in the

table following.

Support and services capitalisation

Property, plant and equipment and investment property

The Group has operated a shared services model with resources centralised in the head office entities in New

Zealand and Australia. These resources support the operation of the village entities, asset management of

existing villages, development of new villages and general administration and compliance activities for the

business as a whole. The cost of a development (whether investment property or plant, property and

equipment) includes directly attributable costs of constructing the development for it to be capable of

operating in the manner intended by the Group. Since the majority of shared services resources support

multiple development projects, an allocation methodology must be applied.

As reported at 31 March 2025, the Group reviewed this allocation methodology and revised its policy, with the

change retrospectively applied. Where completed investment property and property, plant and equipment

are held at fair value, any changes to the historical cost base of assets that had previously been valued, did

not impact the carrying value. The revised policy reduced the cost base of assets, reduced capitalised costs,

increased reported expenses, and increased the fair value movement (investment properties) or asset

revaluation reserve movement (property, plant and equipment). To the extent that property, plant and

equipment had been impaired in previous periods, the policy change also reversed the impairment before

uplifting the asset revaluation reserve. There were also consequential reductions in the annual depreciation

expenses for property, plant and equipment. While these changes were made at 31 March and applied to

previous annual reporting periods, they also required an adjustment to the comparatives for the interim

reporting period.

Intangible assets

The previous methodology saw support and services costs capitalised to all qualifying assets, including

internally generated intangible assets (software). Intangible assets are held at cost less amortisation and

impairment (if any). The change to the policy resulted in a permanent reduction in the value of intangible

assets and an increase in reported expenses. There were also consequential reductions in the annual

amortisation expenses. This also required an adjustment to the comparatives for the interim reporting period.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


8


Investment property gross-up rectification

Subsequent to 31 March 2025, the Group identified the determination of the gross-up adjustment relating to

investment property valuations did not adjust for suspended contributions/loans to residents, which reduced

the occupancy advance liability. As a result, investment property and fair value gains were overstated in the

financial statements for the year ended 31 March 2025.

This matter has been corrected by restating each of the affected financial statement line items for the prior

period, as shown below. Comparative information has been amended accordingly. The correction had no

effect on cash flows, banking covenants, or profit before income tax and fair value movements.

Comparative period impact – consolidated income statement

Mar 2025 Sep 2024

$000 $000


Expenses

Operating expenses – reported (351,706)

Adjustment – capitalised costs (21,699)

Operating expenses – restated (373,405)


Depreciation and amortisation expense – reported (25,403)

Adjustment – capitalised costs 463

Depreciation and amortisation expense – restated (24,940)


Fair value movement

Fair value movement of investment properties – reported 169,173 254,570

Adjustment – capitalised costs - 15,487

Adjustment – investment property gross-up (76,916) -

Fair value movement of investment properties – restated 92,257 270,057


Income tax

Income tax credit – reported (80,440)

Adjustment – capitalised costs (6,614)

Income tax credit – restated (87,054)


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


9


Comparative period impact – consolidated statement of financial position

Mar 2025

$000


Assets

Investment property – reported 10,812,542

Adjustment – investment property gross-up (76,916)

Investment property – restated 10,735,626


Equity

Retained earnings – reported 2,228,679

Adjustment – investment property gross-up (76,916)

Retained earnings – restated 2,151,763


Comparative period impact – consolidated statement of cash flows

Sep 2024

$000


Operating activities

Payments to suppliers and employees – reported (343,892)

Reclassification – capitalised costs (21,699)

Payments to suppliers and employees – restated (365,591)


Investing activities

Purchase of intangible assets – reported (2,510)

Adjustment – capitalised costs 545

Purchase of intangible assets – restated (1,965)


Development of investment property – reported (220,002)

Adjustment – capitalised costs 21,154

Development of investment property – restated (198,848)

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


10


Comparative period impact – earnings per share (EPS)

Mar 2025 Sep 2024


Net profit after tax – reported ($000) (436,831) 94,365

Adjustments ($000) (76,916) (12,363)

Net profit after tax – restated ($000) (513,747) 82,002

Weighted average number of shares (in ’000) 710,192 687,642

Basic EPS (cents per share) – reported (61.5) 13.7

Basic EPS (cents per share) – restated (72.3) 11.9


Net profit after tax – restated ($000) (513,747) 82,002

Fair value of shares to settle share rights ($000) (179) (787)

Adjusted net profit after tax – restated ($000) (513,926) 81,215

Weighted average number of shares (in ’000) 710,192 687,642

Diluted EPS (cents per share) – reported (61.5) 13.6

Diluted EPS (cents per share) – restated (72.4) 11.8


Comparative period impact – net tangible assets (NTA)

Mar 2025


NTA – reported ($000) 4,247,306

Adjustments – investment property gross-up ($000) (76,916)

NTA – restated ($000) 4,170,390

Ordinary shares (in ’000) 1,015,713

NTA per share (cents per share) – reported 418.2

NTA per share (cents per share) – restated 410.6

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


11


New and amended standards and interpretations

The Group adopted all relevant mandatory new and amended NZ IFRS Standards and Interpretations in the

current period. None had a material impact on these consolidated interim financial statements.

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of

issuance of the Group’s interim financial statements are disclosed below. The Group intends to adopt these

new and amended standards and interpretations, if applicable, when they become effective.

NZ IFRS 18 – Presentation and Disclosure in Financial Statements.

This standard becomes effective for reporting periods beginning on or after 1 January 2027. NZ IFRS 18

introduces new requirements on presentation within the statement of comprehensive income, including

specified totals and subtotals. It also requires disclosure of management-defined performance measures and

includes new requirements for the aggregation and disaggregation of financial information based on the

identified ‘roles’ of the primary financial statements and the notes. The effect of these have not yet been

determined.

Climate and seismic risk

For more information refer to the 2025 Annual Report.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


12


2. SEGMENT INFORMATION

The Group operates in a single industry: the provision of integrated aged care centres and retirement villages

for older people in New Zealand and Australia. The service delivery process is consistent across all villages, with

similar customer classes, distribution methods, and regulatory environments. Throughout the period, the Group

has been refining segmentation of care and village operations, however these remain aggregated within

each region until embedded in internal reporting. There has been no change in the segmental reporting

methodology in the current period.

The Group’s chief operating decision maker is the Board of Directors and Chief Executive Officer.



New Zealand

villages

Australia

villages Non-village Group

$000 $000 $000 $000

Sep 2025

Care and village fees 245,641 65,209 - 310,850

Deferred management fees

59,268 18,774 - 78,042

Imputed interest income on refundable

accommodation deposits

4,971 12,109 - 17,080

Other income 5,138 1,178 1,180 7,496

Total operating revenue (adjusted) 315,018 97,270 1,180 413,468


Employee expenses (165,745) (56,131) (30,639) (252,515)

Operations

(32,843) (7,023) (854) (40,720)

Building and grounds (41,309) (7,366) (1,364) (50,039)

Direct selling expenses (1,639) (422) - (2,061)

Marketing (5,278) (2,823) (2,337) (10,438)

Software and technology (406) (135) (8,996) (9,537)

Administration (2,014) (809) (9,760) (12,583)

Capitalised to qualifying assets - - 4,543 4,543

Total operating expenses (adjusted) (249,234) (74,709) (49,407) (373,350)

Operating earnings before interest, tax,

depreciation, amortisation, and fair value

movements (EBITDAF)

65,784 22,561 (48,227) 40,118

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


13



Reconciliation to the net profit/(loss) after tax


1

Non-operating revenue and expenses have been presented in the table below.

New Zealand

villages

Australia

villages Non-village Group

$000 $000 $000 $000

Sep 2024 (restated)

Care and village fees 224,834 52,182 - 277,016

Deferred management fees 59,614 18,151 - 77,765

Imputed interest income on refundable

accommodation deposits 4,701 11,014 - 15,715

Other income 3,848 1,600 1,174 6,622

Total operating revenue (adjusted) 292,997 82,947 1,174 377,118


Employee expenses (154,819) (47,638) (45,657) (248,114)

Operations (32,997) (6,920) (1,525) (41,442)

Buildings and grounds (38,803) (6,504) (1,477) (46,784)

Direct selling expenses (5,902) (1,176) - (7,078)

Marketing (3,450) (302) (7,458) (11,210)

Software and technology (592) (67) (10,678) (11,337)

Administration (2,132) (488) (7,155) (9,775)

Capitalised to qualifying assets - - 12,317 12,317

Total operating expenses (adjusted) (238,695) (63,095) (61,633) (363,423)

Operating earnings before interest, tax,

depreciation, amortisation and fair value

movements (EBITDAF)

54,302 19,852 (60,459) 13,695


Sep 2025

Sep 2024

(restated)

$000 $000

Operating earnings before interest, tax, depreciation, amortisation,

and fair value movements (EBITDAF)

40,118



13,695

Non-operating revenue

1

- (11,967)

Interest received 312

1,112

Non-operating expenses

1

(3,577)

(9,982)

Depreciation and amortisation expense (21,811)

(24,940)

Finance costs (38,967) (53,204)

Imputed interest charge on refundable accommodation deposits (17,080) (15,715)

Impairment losses (2,436) -


Profit/(loss) before income tax and fair value movements (PBTF) (43,441)


(101,001)

Fair value movement of investment properties 3,248

270,057

Income-tax (expense)/credit (5,001)

(87,054)

Net profit/(loss) after tax (NPAT) (45,194)

82,002

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


14


Non-operating revenue and expenses


Operating earnings before interest expense, tax, depreciation, amortisation and fair value movements

(EBITDAF) and non-operating revenue and expenses are a non-GAAP measure which do not have a

standardised meaning prescribed by GAAP (Generally Accepted Accounting Practice). These non-GAAP

measures have been presented as they are used internally by chief operating decision makers to understand

the Group’s performance. It may not be comparable to similar financial information presented by other

entities.

Non-current assets


Non-current assets include property, plant and equipment, investment properties and intangible assets.


Sep 2025 Sep 2024

$000 $000


Reduction to DMF for GST and uncapped transfers - (11,967)

Total non-operating revenue - (11,967)


Other LSS and ESS costs

(115) (1,045)

Organisation transformation costs – redundancy (2,132) (2,888)

Total non-village employee expenses (2,247) (3,933)


Close-out of employee share schemes – consultancy

(50) (477)

Holiday Act 2003 remediation – consultancy

(125) (47)

Organisation transformation costs – consultancy (1,155) (3,647)

Total non-village administration expenses (1,330) (4,171)


Inventory write-downs (non-village)

- (1,878)

Total operations expenses - (1,878)


Total non-operating revenue and expenses (3,577) (21,949)

Sep 2025 Mar 2025

(restated)

$000 $000


New Zealand 9,200,349 9,163,021

Australia

2,755,614 2,606,017

Total 11,955,963 11,769,038

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


15


Loans and borrowings

Sep 2025

Mar 2025

$000 $000


New Zealand 654,511 674,232

Australia 1,005,178 1,008,320

Total 1,659,689 1,682,552

Information about major customers

Included in total revenue is revenue that arose from sales to the Group’s largest customers. The Group derives

care-fee revenue for eligible government-subsidised residents who receive aged residential care, and in

Australia, home care. There are no other significant customers.

Sep 2025 Sep 2024

$000 $000


Health New Zealand – Te Whatu Ora 93,950 86,187

Australian Government Services Australia

37,863 28,178

Total 131,813 114,365

3. OPERATING EXPENSES


Sep 2025

Sep 2024

(restated)

$000

$000


Employee expenses 254,762 252,047

Operations 40,720 43,320

Building and grounds 50,039 46,784

Direct selling expenses 2,061 7,078

Marketing 10,438 11,210

Software and technology 9,537 11,337

Administration 13,913 13,946

Gross operating expenses 381,470 385,722

Capitalised to qualifying assets (4,543) (12,317)

Reported operating expenses 376,927 373,405


The Group revised its cost capitalisation policy in respect of centralised support service costs. While these

changes were made at 31 March 2025 and applied to previous annual reporting periods, they also required

an adjustment to the 30 September 2024 comparatives for the interim reporting period. Additional details can

be found in note 1.

Employee expenses relating to sales advisors, including commission payments, which were previously classified

as direct selling expenses, have been reclassified to employee expenses. This is consistent with the

presentation at 31 March 2025. This amounted to $4.8 million in the six months to 30 September 2024 and was

reclassified in the comparative period.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


16


4. INCOME TAX

Income tax recognised in income statement


Sep 2025

Sep 2024

(restated)


$000 $000

Tax expense comprises:

 Current tax expense - -

 Deferred tax expense/(credit) 5,001 87,054

Total income-tax expense/(credit) 5,001 87,054


The tax rate used in the below reconciliation is the corporate tax rate in New Zealand of 28% (2024: 28%). The

corporate tax rate in Australia is 30% (2024: 30%).

Reconciliation between prima facie taxation and tax expense


Sep 2025

Sep 2024

(restated)

$000 $000

(Loss)/profit before income tax (40,193) 169,056

Income tax expense calculated at 28% (11,254) 47,336

Tax effects of:

 Non-taxable fair value movement of investment property

(1,908) (76,532)

 Property movements

(10,254) 80,384

 Capitalised interest

(2,507) (9,101)

 Non-deductible impairment

682 -

 Tax losses not recognised

25,590 37,218

 Interest deductions not recognised

8,505 8,454

 Other

(3,853) (705)

Total income-tax expense/(credit) 5,001 87,054

Effective tax rate (12.4%) 51.5%

Amounts charged or credited to other comprehensive income or equity


Sep 2025

Sep 2024

(restated)


$000 $000

Tax effect of:


 Revaluation of property, plant and equipment

(231) -

 Fair value movement in cash-flow hedge reserve

(4,767) (8,426)

 Other

(3) 193

Total income-tax expense/(credit) (5,001) (8,233)



RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


17


Deferred tax asset/liability


Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance


$000 $000 $000 $000



Sep 2025


Property, plant and equipment

(109,536) (5,063) (754) (115,353)

Investment properties

(21,827) 4,694 1,505 (15,628)

Deferred management fee

(148,485) (11,216) (1,134) (160,835)

Derivative financial instruments 3,978 (948) 4,823 7,853

Tax losses carry-forwards recognised 254,034 8,009 418 262,461

Other 21,836 (477) 143 21,502

Total deferred tax asset - (5,001) 5,001 -



Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance


$000

$000 $000 $000


Mar 2025

Property, plant and equipment (80,582) 17,026 (45,980) (109,536)

Investment properties 20,503 (42,342) 12 (21,827)

Deferred management fee (137,690) (10,596) (199) (148,485)

Derivative financial instruments (2,897) 23 6,852 3,978

Tax losses carry-forwards recognised 441,614 (188,733) 1,153 254,034

Other 18,635 3,180 21 21,836

Total deferred tax asset 259,583 (221,442) (38,141) -


Unrecognised deductible temporary differences – tax losses

Since 31 March 2025, the Group recognises a deferred tax asset on tax losses only to the extent that it offsets

existing deferred tax liabilities.

The Group has unrecognised tax losses of NZ$571.3 million and A$433.6 million that may be carried forward for

future use, subject to meeting shareholding continuity requirements or, where relevant, the New Zealand and

Australian business continuity tests.

These losses continue to represent a potential future tax benefit, despite not being recognised for accounting

purposes.


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


18


New Zealand

Sep 2025 Mar 2025

$000 $000


Tax losses – revenue 1,458,155 1,378,782

Tax losses – capital

- -

Total tax losses available 1,458,155 1,378,782


Recognised tax losses 886,831 873,118

Unrecognised tax losses 571,324 505,664

Total tax losses 1,458,155 1,378,782


Australia

Sep 2025 Mar 2025

A$000 A$000


Tax losses – revenue 449,348 415,521

Tax losses – capital

25,619 25,619

Total tax losses available 474,967 441,140


Recognised tax losses 41,364 28,964

Unrecognised tax losses

433,603 412,176

Total tax losses 474,967 441,140

Unrecognised deductible temporary differences – other

Thin capitalisation interest limitation rules in Australia limit net interest deductions to 30% of an entity’s tax

EBITDA (which is broadly based on the concept of taxable income before interest and depreciation). The

Australian subsidiaries’ current tax profile means they are denied a deduction for their net interest costs in the

current period but are permitted to carry forward the denied interest deductions for up to 15 years, subject to

satisfying certain integrity rules at the time the denied interest deductions are sought to be recouped. Denied

interest deductions relate to interest incurred on Australian borrowings secured over New Zealand assets. The

disclosed balance has been determined on the assumption that the amount and interest rate on these

borrowings is consistent with arm’s length terms. Should the Group pursue the use of these deductions, it

intends to undertake an analysis to validate this assumption, and the outcome may result in an adjustment to

the disclosed balance. The Group has decided to not recognise a deferred tax asset in respect of its denied

net interest deductions.


Sep 2025 Mar 2025

A$000 A$000

Denied interest deductions – Australian subsidiaries 101,959 76,666


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


19


5. ASSETS HELD FOR SALE

Investment property held for sale is measured at fair value. Revaluations to fair value are based on either sale

price or an independent valuation report prepared by registered valuers, CBRE Limited and Jones Lang

LaSalle Advisory Services Pty Ltd, at the reporting date in line with NZ IFRS 13 – Fair Value Measurement.

The Karori land (Wellington, New Zealand) is subject to an unconditional sale and purchase agreement for

$23.0 million. This was settled subsequent to reporting date.

Excess land at Nellie Melba (Melbourne, Australia) is subject to an unconditional contract of sale for A$9.0

million ($9.9 million), with settlement expected in H2 FY26.

The land at Park Terrace (Christchurch, New Zealand) and Mt Eliza (Melbourne, Australia), which was

subsequently sold, and the Coburg North site (Melbourne, Australia), which is actively marketed, did not meet

the criteria for classification as ‘held for sale’ under NZ IFRS 5 at 30 September 2025.

Sept 2025 Mar 2025

$000 $000


Opening balance 32,926 86,424

Net additions/(disposals)

- (6,613)

Transfer to investment property - (20,984)

Fair value movement - (25,901)

Foreign-currency exchange movements 359 -

Closing balance 33,285 32,926

6. PROPERTY, PLANT AND EQUIPMENT

Independent valuations of the aged care centre occur at annual reporting dates. Revaluations are made

with sufficient regularity to ensure that the carrying amount does not differ materially from that which would

be determined using fair value. The Group assesses whether indicators of a significant change in fair value

exist at the interim reporting date, and where no such indicators are present, the independent valuations

recorded at the last annual reporting date are considered to remain appropriate.

In the current period, three aged care centres were valued out-of-cycle by CBRE Limited to reflect changes in

the underlying asset:

Woodcote and Margaret Stoddart aged care centres

Woodcote and Margaret Stoddart aged care centres (Christchurch, New Zealand) will close, with residents

being transferred to other Ryman facilities in the area. The market value of the care centre was assessed on a

vacant possession basis. The valuation considered a capitalisation of pro-forma EBITDAR under a going

concern scenario (assuming a trade-up period) and comparable transactions using a dollar-per-bed metric

based on market evidence. The valuer apportioned the total value between land and buildings.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


20


Kevin Hickman aged care centre

Kevin Hickman aged care centre (Christchurch, New Zealand) was completed and opened in the period. At

31 March 2025, following the impairment of a number of recently opened facilities, an internal desktop

assessment was undertaken, which concluded that an impairment charge should be recognised for this

centre. This was a management valuation using a market rental per bed and capitalisation rate

benchmarked against comparable villages which were independently valued. In the current period, it has

now been valued by CBRE Limited. The independent valuation at 30 September 2025 is broadly in line with

management assumptions at 31 March 2025, with impairment reflecting cost variations.

The care centre valuation methodology for completed assets remains unchanged from that applied at 31

March 2025. For further details, refer to the 2025 Annual Report.

Valuation

Margaret

Aged care centre valuation Woodcote Stoddart Kevin Hickman

$000 $000 $000


Carrying value at 30 September 2025

3,582 3,583 14,804

Independent valuation at 30 September

2025

2,350 2,550 13,600

Fair value movement (1,232) (1,033) (1,204)

Recognised within:

Asset revaluation reserve - (1,033) -

Impairment expense (1,232) - (1,204)


As the fair value of land and buildings is determined using inputs that are unobservable (such as capitalisation

rates and market value per care bed), the Group has categorised property, plant and equipment as Level 3

under the fair value hierarchy in line with NZ IFRS 13 – Fair Value Measurement.

The independent valuer assumed a market rental value of $191 per bed per week for Kevin Hickman. A

significant increase (decrease) in the market rental value may result in a higher (lower) fair value

measurement.

7. INVESTMENT PROPERTIES


Sep 2025

Mar 2025

(restated)


$000 $000


Opening balance 10,735,626 10,142,199

Additions (including transfers to/from property, plant and

equipment)

95,374 437,521

Fair value movement 3,248 118,158

Transfers (to)/from assets held for sale (note 5) - 20,984

Net foreign-currency exchange movements 79,704 16,764

Closing balance 10,913,952 10,735,626


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


21


The 31 March 2025 balance has been restated to adjust for the portion of suspended contributions which were

reflected in the valuation by the independent valuer. Further detail is included in note 1.

Valuation reconciliation

A reconciliation between the valuation and the amount recognised as investment property is as follows:


Sep 2025

Mar 2025

(restated)

$000 $000


Subject to valuation


Operators interest 4,083,780 3,972,918

Completed new units not occupied, and repaid resale units 656,644 616,556

Development land – land bank 376,103 368,692

Development land – construction sites 62,598 64,196

Commercial property 16,600 16,400


Held at cost

Work in progress – construction WIP

150,366 283,499


Adjustments

Revenue in advance 216,931 184,020

Gross occupancy advance 6,409,598 6,166,971

Accrued DMF (903,755) (830,449)

Suspended contributions (resident loans) (128,223) (76,916)

Occupancy advance adjustments (26,690) (30,261)

Total investment property 10,913,952 10,735,626


As required by NZ IAS 40 – Investment Property, the fair value as determined by the independent registered

valuer is adjusted for assets and liabilities already recognised on the balance sheet which are also reflected in

the discounted cash flow analysis.

The occupancy advance adjustments relate to differences between the value of net occupancy advances

included for future repayment within the independent valuation and the net occupancy advances on the

balance sheet. These differences arise when a unit has multiple occupancy advances and only one

occupancy advance is included within the valuation cash flows. This adjustment is made to ensure the total

adjustment to the independent valuation of completed units is consistent with the liabilities included within the

independent valuation of completed units.


Sep 2025 Mar 2025


Units included in the valuation


Currently occupied, and vacant not repaid units 8,996 8,898

Completed new units not occupied, and repaid resale units

962 881

Total units included in the valuation 9,958 9,779


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


22


Independent valuation

Fair value of investment property is determined by independent registered valuers, CBRE Limited and Jones

Lang LaSalle Advisory Services Pty Ltd, at the interim reporting date. All valuers are registered valuers and

industry specialists in valuing the retirement living sector. These valuations consider the requirement of NZ IFRS

13 – Fair Value Measurement to assume that market participants act in their economic best interests. The

valuation was a desktop review following full valuations completed at 31 March 2025.

For retirement village assets, the predominant form of cash flow is roll-over of occupation right agreements

which typically occurs on the departure of village residents. Where fair value is able to be reliably measured,

the independent valuer uses a discounted cash flow methodology, which estimates the present value of

future cash flows from occupation right agreements, deferred management fees, and village fees.

Development land is valued using the direct comparison approach, whereby recent sales of block land

preferably of similar potential and characteristics in terms of size, average section realisation values and

development costs have been compared to the relevant Group property. Consideration is then given to the

individual characteristics of the Group’s property including consent status.

As the fair value of investment property is determined using inputs that are unobservable, the Group has

categorised investment property as Level 3 under the fair value hierarchy, in line with NZ IFRS 13 – Fair Value

Measurement. NZ IFRS 13 requires that the inputs are consistent with the characteristics of the asset that a

market participant would take into account in a transaction for the asset.

The independent valuers used a range of significant assumptions as follows:

Sep 2025 Mar 2025

New Zealand Australia New Zealand Australia

% % % %

Growth rate (nominal) – year 1 to 4 0.0–3.0 0.0–2.5 0.0–3.0 0.0–2.5

Growth rate (nominal) – year 5+ 2.5–3.5 1.8–3.5 2.5–3.5 1.8–3.5

Discount rate 13.0–16.5 13.0–14.0 13.0–16.5 13.0–14.0

Sensitivity

A change in the independent valuers’ assumptions would impact the fair value measurement of investment

property as follows:


Adopted

value

Discount rate

-50 bp

Discount rate

+50 bp

Growth rate

-50 bp

Growth rate

+50 bp

$000 $000 $000 $000 $000


Sep 2025

Operators interest 4,083,780

Difference 175,570 (168,130) (245,147) 263,209

Mar 2025

Operators interest 3,972,918

Difference 146,921 (183,673) (270,004) 244,880


RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


23


Other inputs used in the fair value measurement of the Group’s investment property portfolio include the

average age of residents and the stabilised departing occupancy periods. An increase in the average age of

residents or decrease in the occupancy periods would result in a higher fair value measurement. Conversely, a

decrease in the average age of residents or increase in the occupancy periods would result in a lower fair

value measurement.

Sep 2025 Mar 2025

Portfolio range / portfolio

weighted average New Zealand Australia New Zealand Australia


Independent current average

age

75–88 / 83.0 78–87 / 83.0 75–88 / 82.8 78–87 / 82.9

Serviced current average age

68–92 / 87.6 84–91 / 87.5 80–92 / 87.6 84–91 / 87.7

Independent stabilised

departing occupancy period

6.8–8.6 / 8.0 7.5–8.8 / 8.0 6.6–8.6 / 8.0 7.5–8.9 / 8.0

Serviced stabilised departing

occupancy period

3.8–4.7 / 4.2 4.3–5.0 / 4.6 3.9–4.7 / 4.2 3.9–5.0 / 4.6


Market risk

Property markets in both Australia and New Zealand remain subject to heightened uncertainty. In Australia,

the valuer comments that cost inflation, interest rate changes and consumer confidence are resulting in a

more volatile transaction market. Transactions across markets and sectors remain low. While the market

remains functional, continued volatility combined with rising interest rates poses a risk of impacting pricing.

In New Zealand, the valuer comments that the property market showed resilience post-COVID-19 with strong

demand for prime assets, but tightening credit and higher interest rates from 2022 to 2024 led to subdued

large-scale transactions and prolonged market inertia. Recent interest rate cuts have improved sentiment,

encouraging renewed buyer activity, though recovery for major transactions is expected to be gradual.

Contrary to the general property market, appetite for prime retirement village assets remains strong, while

secondary stock with functional obsolescence faces weaker demand.

The valuers reiterate that their conclusions are based on data and market sentiment as at the date of

valuation. For the avoidance of doubt, this does not constitute a ‘material valuation uncertainty’.

Capitalised WIP


No costs have been capitalised to land bank sites in the current period.


Sep 2025 Mar 2025

$000 $000


Sites which have commenced construction 150,366 287,530

Sites which are classified as land bank - -

Total capitalised WIP 150,366 287,530

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


24


8. SHARE CAPITAL

Sep 2025 Mar 2025 Sep 2025 Mar 2025

Shares

‘000

Shares

’000 $000 $000


Total ordinary shares (including treasury stock) at 1 April 1,015,713 687,642 1,923,044 952,887

Ordinary shares issued:


- Long term incentive plan 16 - 58 -

- Equity raise - 328,071 - 970,157

Total closing ordinary shares (including treasury stock) 1,015,729 1,015,713 1,923,102 1,923,044


All ordinary shares rank equally with one vote attached to each fully paid ordinary share. The shares have no

par value. The Group incurred no transaction costs issuing shares during the period (31 March 2025: $30.5

million).

Shares purchased on market under the leadership share scheme are treated as treasury stock until they are

vested to the employees and are included in the total ordinary shares. Treasury stock consists of 995,065 shares

(31 March 2025: 1,170,990).

Basic and diluted earnings per share (EPS)


Sep 2025

Sep 2024

(restated)



Net profit/(loss) after tax ($000) (45,194) 82,002

Weighted average number of shares (in ’000)

1,015,716 687,642

Basic EPS (cents per share) (4.4) 11.9


Net profit/(loss) after tax ($000) (45,194) 81,215

Weighted average number of shares (in ’000)

1,015,716 687,642

Diluted EPS (cents per share) (4.4) 11.8


Diluted earnings per share for 30 September 2024 were calculated with the assumption that shares were

purchased from market to settle the share rights, rather than issuing new shares, as at that time the Board had

not determined their preferred approach. The purchase of shares from the market to settle share rights does

not affect the number of outstanding ordinary shares or the income statement. However, it does impact

equity and is considered dilutive when share rights are out of the money.

The Board has since confirmed its intention to issue shares rather than purchasing on market and did so during

the period. There is no dilutive impact on earnings per share for the six months ended 30 September 2025, as

the Group is in a loss-making position.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


25


Net tangible asset (NTA) per share


Sep 2025

Mar 2025

(restated)



NTA ($000) 4,123,365 4,170,389

Ordinary shares at reporting date (in ’000) 1,015,729 1,015,713

NTA per share (cents per share) 406.0 410.6


NTA is calculated as total assets less intangible assets and deferred tax assets, and less total liabilities.

9. TRADE AND OTHER RECEIVABLES

Sep 2025 Mar 2025

$000 $000


Care and village fees receivables 24,375 22,902

Allowance for expected credit losses

(685) (800)

Net trade receivables 23,690 22,102

New sale occupancy advance debtors 18,113 20,625

Resale occupancy advance debtors 86,159 91,677

Refundable accommodation deposit receivables 3,030 5,505

Prepayments and other receivables 18,509 24,012

Total trade and other receivables 149,501 163,921

10. TRADE AND OTHER PAYABLES


Sep 2025 Mar 2025

$000 $000


Trade payables 70,830 85,089

Land purchase accruals 7,500 9,500

Other payables 22,798 18,989

Total trade and other payables 101,128 113,578


Trade payables are typically paid within 30 days of the invoice date or on the 20

th

of the month following the

invoice date.

Land purchase accruals relate to acquisitions where the Group has settled the purchase but negotiated

deferred payment terms as part of the purchase agreement.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


26


11. INTEREST-BEARING LOANS AND BORROWINGS

At reporting date, interest-bearing loans and borrowings include secured bank loans and unsubordinated

fixed-rate retail bonds (31 March 2025: secured bank loans and unsubordinated fixed-rate retail bonds).

Sep 2025 Mar 2025

$000 $000


Bank loans 1,512,657 1,536,436

Retail bonds – RYM010

150,000 150,000

Total loans and borrowings at face value 1,662,657 1,686,436

Issue costs for bank loans capitalised (2,251) (2,885)

Issue costs for the retail bonds capitalised (717) (999)

Total loans and borrowings 1,659,689 1,682,552



Total drawn loans 1,662,657 1,686,436

Facility headroom 576,681 522,838

Total facility limits 2,239,338 2,209,274


In addition to the above, the Group has an unarranged Institutional Credit Agreement that provides a

$2,850,000 overdraft facility.

Details of the Group’s interest-bearing loans and borrowings, including covenant requirements and maturity

dates, are disclosed in the 2025 Annual Report. These remain unchanged as at 30 September 2025, consistent

with the position at 31 March 2025.

A breakdown of movements in total borrowings is presented in the following table.

Sep 2025 Mar 2025

$000 $000


Opening balance 1,682,552 2,546,947

Drawdown/(Repayment) of bank loans (net) (60,255) (606,105)

Drawdown/(Repayment) of Institutional term loan - (275,088)

Fair value adjustment on hedged borrowings movements - 5,909

Foreign exchange movements 36,476 7,694

Movements in prepaid issue costs 916 3,195

Closing balance 1,659,689 1,682,552


Refinancing

Subsequent to the reporting period, the Group refinanced its bank loan facilities. Changes to funding

arrangements including a restructure of facilities, revised pricing and extension of bank loan maturity. Further

detail is included in note 16 Subsequent events.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


27


Security

The bank loans and retail bonds are secured by a General Security Deed over the parent and subsidiary

companies and supported by mortgages over the freehold land and buildings and a General Security

Agreement (GSA). The GSA and mortgages are first ranking, other than when subordinated to the statutory

supervisor who holds registered mortgages for the benefit of residents over:

 The aged care centres, as security for residents’ refundable accommodation deposits and

occupancy advances; and

 The retirement village (excluding aged care centres), as security for residents’ occupancy advances

(see note 13).

The subsidiary companies have all provided guarantees for the Group’s secured loans as parties to the

general security agreement.

Covenants

The Group is subject to capital requirements imposed by its bank and the lenders included in the banking

syndicate through covenants agreed as part of the lending facility arrangements, and bond holders through

covenants in the Master Trust Deed.

The covenants are tested six monthly at 30 September and 31 March, and the Group has complied with all

amended covenants during the period, noting that the ICR is waived for 31 March 2025, 30 September 2025

and 31 March 2026.

Fair value

Below is a comparison of the carrying amounts and fair values of the interest-bearing loans and borrowings.

The carrying amounts of bank loans are the same as their fair values in all material aspects due to their interest

rate profiles.

Sep 2025 Mar 2025

Carrying amount Fair value Carrying amount Fair value

$000 $000 $000 $000

Unsubordinated

fixed-rate retail bonds

149,283 146,385 149,001 143,370


The fair value of the unsubordinated fixed-rate retail bonds is based on the price traded on the NZX market at

the reporting date. The fair value of the retail bond is categorised as Level 1 under the fair value hierarchy in

accordance with NZ IFRS 13 – Fair Value Measurement.

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


28


12. DERIVATIVE FINANCIAL INSTRUMENTS

At reporting date, the Group’s derivative financial instruments consist of interest rate swaps and collars (31

March 2025: interest rate swaps and collars).

Fair value

These derivatives are initially recognised at fair value on the date the derivative contract is entered into and

remeasured to their fair values at each reporting date. The fair values of these derivatives are categorised as

Level 2 under the fair value hierarchy in NZ IFRS 13 – Fair Value Measurement. The fair value of these derivative

instruments is derived using inputs supplied by third parties that are observable, either directly (prices) or

indirectly (derived from prices). The fair value of interest rate swaps is determined by discounting the future

cash flows using the yield curves at the end of the reporting period and the credit risk inherent in the contract.

Modified interest rate swaps

The Group historically modified interest rate swaps to reduce near term interest rate costs which resulted in the

original hedge relationship being discontinued. At discontinuation, the swaps had mark-to-market gains. As

the hedged cash flows are still expected to occur the gains remain in the cash-flow hedge reserve and will be

reclassified to income statement over the original hedge period.

Gains released to interest expense in the period:

Sep 2025 Sep 2024

$000 $000

Amount reclassified to P&L

Interest expense/(credit) (4,181) (3,207)


Gains remaining in the cash-flow hedge reserve which will be reclassified over the original hedge period:

Sep 2025 Mar 2025

$000 $000

Cashflow hedge reserve

Unamortised balance (excluding tax effect) 12,643 16,771

13. OCCUPANCY ADVANCES

Sep 2025 Mar 2025

$000 $000

Gross occupancy advances

Opening balance 6,166,971 5,596,912

Gross receipts – occupation rights agreements for new units 166,906 403,929

Net receipts – occupation rights agreements for resale units 32,627 157,466

Net foreign-currency exchange differences 43,094 8,664

Closing balance 6,409,598 6,166,971



Net occupancy advances

Less deferred management fees

(903,755) (830,449)

Less suspended contributions (resident loans) (128,223) (119,364)

Closing balance 5,377,620 5,217,158

RYMAN HEALTHCARE LIMITED
Notes to the consolidated interim financial statements

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025


29


14. COMMITMENTS

The Group had commitments relating to construction contracts amounting to $67.4 million at 30 September

2025 (31 March 2025: $88.0 million).

The Group has an ongoing commitment to maintain the land and buildings of the integrated retirement

villages, rest homes and hospitals.

15. CONTINGENT LIABILITIES

There are no material contingent liabilities at 30 September 2025 (31 March 2025: nil).

16. SUBSEQUENT EVENTS

Restructure of bank loan facilities

In November 2025, the Group successfully refinanced its $2,048 million syndicated loan facilities, delivering

improved pricing on loan margins and line fees, along with maturities ranging from 4.5 to 7.0 years and a pro-

forma weighted average term of 5.0 years as at 30 September 2025.

Key covenants include an Interest Cover Ratio (ICR) of 1.50x from September 2026, calculated on a rolling 12-

month adjusted EBITDA to interest (excluding development debt interest) and tested semi-annually. The Group

also remains subject to an adjusted total liabilities-to-net tangible assets ratio of 1.0x.

Development debt remains subject to lender-approved controls. Development debt is based on forecast net

cash proceeds for committed developments and the cost of New Zealand care centres under development

or opened in the past 24 months. Development debt for new projects is included once lenders approve the

Group’s feasibility and substantive steps towards the development have commenced.

Land sales

In November 2025, the Group entered sale and purchase agreements to sell:

 Park Terrace (Christchurch, New Zealand) – Total consideration of $42.0 million, broadly in line with

carrying value. Settlement is expected in FY27.

 Mt Eliza (Melbourne, Australia) – Total consideration of A$30.5 million ($34.8 million), broadly in line with

carrying value. Settlement is expected in H2 FY26.

The settlement of the Karori land, which had previously been classified as held for sale, was completed after

balance date.

Dividend

The directors have determined that no final dividend will be paid relating to the interim period.

Other

There have been no other events subsequent to 30 September 2025 that materially impact on the results

reported.


PwC New Zealand, PwC Tower, 15 Customs Street West, Private

Bag 92162, Auckland 1142, New Zealand

T: +64 9 355 8000, www.pwc.co.nz


pwc.co.nz

Independent auditor’s review report

To the shareholders of Ryman Healthcare Limited

Report on the consolidated interim financial statements

Our conclusion

We have reviewed the consolidated interim financial statements of Ryman Healthcare Limited (the Company) and

its subsidiaries (the Group), which comprise the consolidated statement of financial position as at 30 September

2025, and the consolidated income statement, the consolidated statement of comprehensive income, the

consolidated statement of changes in equity and the consolidated statement of cash flows for the six months ended

on that date, and selected explanatory notes.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying

consolidated interim financial statements of the Group do not present fairly, in all material respects, the financial

position of the Group as at 30 September 2025, and its financial performance and cash flows for the six months

then ended, in accordance with International Accounting Standard 34 Interim Financial Reporting (IAS 34) and

New Zealand Equivalent to International Accounting Standard 34 Interim Financial Reporting (NZ IAS 34).

Basis for conclusion

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised)

Review of Financial Statements Performed by the Independent Auditor of the Entity (NZ SRE 2410 (Revised)).

Our responsibilities are further described in the Auditor’s responsibilities for the review of the consolidated interim

financial statements section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to

the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance

with these ethical requirements.

In our capacity as auditor and assurance practitioner, our firm also provides other assurance services. Our firm also

carries out other services relating to the provision of whistleblower services to the Group. In addition, certain

partners and employees of our firm may deal with the Group on normal terms within the ordinary course of trading

activities of the business. The firm has no other relationship with, or interests in, the Group.

Other matter

The comparative information presented for the six months ended 30 September 2024 was not reviewed or audited.

We were not engaged to perform a review of that comparative interim financial information and, accordingly, we do

not express a conclusion on the comparative information.

PwC – Independent auditor’s review report
Responsibilities of the Directors for the consolidated interim financial

statements

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of

these consolidated interim financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal

control as the Directors determine is necessary to enable the preparation and fair presentation of the consolidated

interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s responsibilities for the review of the consolidated interim financial

statements

Our responsibility is to express a conclusion on the consolidated interim financial statements based on our review.

NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to

believe that the consolidated interim financial statements, taken as a whole, are not prepared in all material

respects, in accordance with IAS 34 and NZ IAS 34.

A review of consolidated interim financial statements in accordance with NZ SRE 2410 (Revised) is a limited

assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons

responsible for financial and accounting matters, and applying analytical and other review procedures. The

procedures performed in a review are substantially less than those performed in an audit conducted in accordance

with International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance

that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated interim

financial statements.

Who we report to

This report is made solely to the Company’s Shareholders, as a body. Our review work has been undertaken so that

we might state those matters which we are required to state to them in our review report and for no other purpose.

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company

and the Company’s Shareholders, as a body, for our review procedures, for this report or for the conclusion we have

formed.

The engagement partner on the review resulting in this independent auditor’s review report is Samuel

Shuttleworth.


For and on behalf of:

PricewaterhouseCoopers Auckland

26 November 2025

31

---

Results for announcement to the market
Name of issuer Ryman Healthcare Limited

Reporting Period 6 months to 30 September 2025

Previous Reporting Period 6 months to 30 September 2024 (restated)

CurrencyNZD

Amount (000s) Percentage change

Revenue from continuing

operations

$413,780 12.97%

Total Revenue $413,780 12.97%

Net profit/(loss) from continuing

operations

$(45,194) -155.11%

Total net profit/(loss) $(45,194) -155.11%

Interim/Final Dividend

Amount per Quoted Equity Security No dividend is to be paid for the 6 months ended 30 September 2025.

Imputed amount per Quoted Equity

Security

N/A

Record Date N/A

Dividend Payment Date N/A

Current period Prior comparable period

Net tangible assets per Quoted

Equity Security (in dollars and cents

per security)

$4.060

$4.106 (31 March 2025 restated)

$4.182 (31 March 2025 reported)

A brief explanation of any of the

figures above necessary to enable

the figures to be understood

Prior comparative periods have been restated. Refer to Note 1 of the

Consolidated Interim Financial Statements for explanation.

Authority for this announcement

Name of person


authorised to make

this announcement

Morgan Powell

Contact person for this

announcement

Matt Prior

Contact phone number +64 3 366 4069

Contact email address matt.prior@rymanhealthcare.com

Date of release through MAP


27 November 2025

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.